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9Abstract 
Glioblastoma (GBM) is the most frequent and malignant brain tumour, where the 
patients’ median survival after diagnosis is only 14.6 months. Therefore, concerted 
research is required to develop novel treatments that will improve patients’ outcome. 
Immunotherapy is one of the promising strategies for novel treatment. However, GBM 
develops multiple mechanisms of immune suppression and escape from immune 
surveillance. Moreover, steroids, chemotherapy and radiotherapy render GBM patients 
immunocompromised. These aspects need to be taken into consideration prior to 
development of immunotherapy tailored to GBM patients.  
Natural killer (NK) cells are large, granular lymphocytes that are able to recognise and 
kill tumour cells and virus – infected cells without prior sensitization and co-
stimulation. Therefore, they might be one of the most potent effectors for use in an 
immunotherapy. However, there is currently a great paucity of studies investigating 
their potential as therapeutic agents for GBM. 
This study confirmed the prognostic significance of elevated T cell infiltration into the 
tumour in GBM patients. However, NK cells represented a minor population in the 
tumour microenvironment. Several mechanisms of the tumour’s escape from immune 
attack were identified, including the induction of a novel population of CD8+CD28-
Foxp3+ regulatory T cells and expression of CD73 and CD39 ectonucleotidases. 
Tumour cells expressed classical HLA class I molecules that are ligands for inhibitory 
killer immunoglobulin-like receptors (KIRs) mediating NK cells tolerance towards self 
cells. Tumour infiltrating macrophages/microglia displayed phenotypic features that 
were indicative of their tolerisation by the CD8+CD28-Foxp3+ regulatory T cells. These 
features include: (1) down-regulated expression of CD40, CD80 and CD86 co-
stimulatory molecules and (2) up-regulated expression of immunoglobulin-like 
transcripts 2, 3, 4 (ILT2,3,4). In the systemic circulation, decreased T helper (Th) cells, 
up-regulated expression of the inhibitory receptor CTLA-4 on the Th cells and 
increased plasma concentration of IL-10 were identified in GBM patients’ blood 
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compared to healthy controls. Despite these integrated mechanisms of tolerance and 
immunological escape, a proportion of the tumour cells might be susceptible to 
immune cell – mediated cytotoxicity due to their expression of Fas ligand, and MICA 
stress – induced ligand for NK cell NKG2D activating receptor.  
Thus, taking into consideration the GBM patients’ local and systemic immune 
suppression and escape, we hypothesised that the use of allogeneic NK cells in a KIR 
receptor – HLA ligand mismatch setting might be an amenable strategy against GBM 
cells. We demonstrated that allogeneic, ex vivo cultured NK cells efficiently lysed 
GBM cells in vitro and in vivo. However, the NK cell efficacy was donor – dependent. 
The presence of KIR2DS2 and KIR2DS4 genes in donors’ NK cells correlated with 
increased cytotoxicity in vitro and this effect was partially independent of the 
inhibitory KIR genes repertoire. Intracranial injection of a single dose of 106 allogeneic 
ex vivo cultured NK cells improved the survival of GBM – bearing mice compared to 
controls. NK cells obtained from donor possessing KIR2DS2 and KIR2DS4 genes 
were more effective than NK cells missing these genes and manifested in prolonged 
animals’ median survival, increased tumour cell apoptosis, decreased proliferation and 
diminished angiogenesis. In contrast, treatment with double doses of 106 NK cells from 
each donor did not result in improved survival. We observed increased recruitment of 
macrophages into the brain parenchyma of all NK cell treated animals compared to 
controls. However, the animals receiving single dose of NK cells exhibited higher 
proportions of F4/80+ macrophages that expressed the IL-7 receptor (CD127), while 
higher proportions of microglia expressed CD40 co-stimulatory molecules compared to 
control group. The tumour cells up-regulated the expression of nestin and HLA-ABC 
after single dose NK cell treatment as a response to inflammation.  
In summary, this work provides the rationale for using allogeneic NK cells against 
GBM and indicates possible targets for adjuvant immunotherapy, such as the CTLA-4 
inhibitory receptor and the targets of CD8+CD28-Foxp3+ regulatory T cells – induced 
immunotolerisation. Moreover, the results of the effect of KIR2DS2 and KIR2DS4 in 
NK cell – mediated cytotoxicity against GBM provide a novel insight into tumour 
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immunology. However, further research is required to evaluate the safety and efficacy 
of allogeneic NK cell – based therapy and to confirm the role of activating KIR 
receptors in determining the potency of NK cells against solid tumours. 
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1. Introduction 
Cancer is a disease affecting 12.7 million people worldwide every year [4]. Despite 
concerted efforts towards developing novel, more effective therapies, the mortality is 
still very high, with 7.6 million deaths every year [4]. According to the Global Burden 
of Disease, Injuries and Risk Factors Study 2010 (GBD 2010), cancer was the major 
cause of death globally in 2010, accounting for 15.1% of all deaths worldwide [5]. The 
estimated cancer incidence in Europe in 2012 was 355.7 new reported cases per 
100000, with the highest incidence in Northern and Western European countries 
(Fig.1) [6]. Within all European countries, Norway has the second highest estimated 
cancer incidence of 451.2 per 100000 reported in 2012 [1, 6]. Moreover, the general 
cancer incidence in the western world has been steadily increasing the last decades, 
mainly due to life style choices such as tobacco smoking, obesity, but also due to the 
extended life expectancy and improved diagnostics. 
Figure 1. Estimated incidence of cancer from all sites except non-melanoma skin  
New reported incidences for 
both sexes in Europe, 2012. 
Demographics obtained from 
European Cancer Observatory: 
Cancer Incidence, Mortality, 
Prevalence and Survival in 
Europe. Version 1.0 (September 
2012) European Network of 
Cancer Registries, International 
Agency for Research on Cancer. 
Available from http://eco.iarc.fr. 
[1]
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1.1 The hallmarks of cancer 
Cancer is a group of diseases that vary histologically depending on the putative cell of 
origin. Moreover, cancer is no longer considered as a homogenous mass of 
proliferating malignant cells, but rather, it is now viewed as heterogeneous tumour 
tissues that actively interact with their surrounding and permeating microenvironment. 
However, there are several features that are common for all cancers, described by 
Hanahan and Weinberg as the hallmarks of cancers (Fig.2) [7, 8].  
Figure 2. Hallmarks of cancer. This figure summarizes characteristic features common for all 
cancers. Red and blue frames indicate emerging and enabling hallmarks, respectively. Figure obtained 
and modified from [7]. Reprinted with permission.
Cancer is characterised by uncontrolled growth and unlimited cell division due to 
acquired ability of sustaining autocrine proliferative signals, avoiding growth 
suppressing mechanisms and avoiding cell death (Fig. 2) [8]. These three hallmarks are 
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the result of a series of gain of function mutations affecting proto-oncogenes and loss 
of function mutations affecting tumour suppressor genes. All healthy cells possess 
multiple mechanisms of DNA repair and sensors of DNA damage that either remove 
the mutation or trigger the programmed cell death to prevent cells with altered DNA 
from proliferating. However, if this system is affected, cells accumulate mutations with 
each division. Therefore, genomic instability has been proposed as a feature enabling 
malignant transformation (Fig. 2) [7]. Moreover, cancer cells acquire unlimited 
replicative potential due to restored activity of telomerase [8]. In order to maintain the 
supply of nutrients and metabolic waste removal, tumour cells induce angiogenesis, a 
process of new blood vessel formation from the sprouting of existing vasculature [8]. 
Rapid cell growth and proliferation of tumour cells frequently result in reprogramming 
the metabolism, therefore this feature has been proposed as one of the new emerging 
hallmarks (Fig. 2) [7]. Eventually, malignant cells are able to invade blood or 
lymphatic vessels and migrate to distant parts of the body to give rise to new tumours 
in a process called metastasis [8]. Recently the immune system has been postulated to 
play an important role in tumour progression. On the one hand, immune cells are able 
to recognise and eliminate transformed cells thus preventing tumour development as 
well as protecting from metastasis. Tumour cells have been shown to develop multiple 
mechanisms to escape immune defence, therefore this has been proposed as a new 
emerging hallmark of cancer (Fig. 2) [7]. However, chronic inflammation resulting 
from immune response has been shown to promote tumour growth due to release of 
growth, survival and pro-angiogenic factors. Thus, the inflammation has been 
proposed as a feature enabling tumour progression (Fig. 2) [7].  
All the above described hallmarks of cancer not only represent features common for all 
cancers, but also indicate key therapeutic targets, such as, for example, inhibiting the 
vascular endothelial growth factor (VEGF) signalling to target angiogenesis. 
Nevertheless, the main challenges in treating cancer are: (1) to remove all abnormal 
cells within the heterogeneous tumour (2) to overcome the tumour’s multiple 
mechanisms of avoiding cell death and (3) to selectively target tumour cells without 
damaging the normal tissue. In addition, the malignant cells often develop multiple 
18
mechanisms of drug-resistance. Therefore, multiple or non-selective treatment 
strategies might be required to eliminate all cancer cells. However, such approaches 
result in side effects, as they inevitably affect also the normal, healthy cells. 
1.2 Brain tumours 
Primary brain tumours are neoplasms originating from intracranial, neuroepithelial 
tissues and they account for approximately 1,4% of all cancers [9]. The incidence of 
brain and central nervous system (CNS) tumours increases with age and is higher in 
males than females (Fig. 3) [4].  
Figure 3. Age-specific incidence of brain and CNS cancer in males and females. In 
each age group the incidence rate of brain and CNS cancer is higher in males (red line) than females 
(green line). Data obtained from GLOBOCAN 2008 v2.0 [4]. Available from: http://globocan.iarc.fr
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To date, the only known risk factor related to brain tumours is an early exposure to 
ionising radiation at therapeutic doses in childhood [9, 10]. Incidence of astrocytic 
gliomas is increased in children with acute lymphocytic leukemia who have had prior 
brain radiotherapy. Also several heritable genetic disorders, like tuberous sclerosis, 
neurofibromatosis and nevoid basal cell carcinoma syndrome have been linked to 
predisposition to brain tumours [9], however, only about 5% of primary brain tumors 
have known hereditary factors. On the other hand, it has been shown that diseases such 
as asthma and allergies are related to decreased risk of developing brain tumour [10]. 
1.2.1 Classification of brain tumours  
Brain tumours are classified according to a system established by the World Health 
Organisation (WHO) where the tumours are categorised by histological features 
depending on their resemblance to the putative cell of origin [11]. For example, 
tumours exhibiting morphological and histological features of astrocytes, such as 
expression of glial fibrilliary acidic protein (GFAP), are classified as astrocytic 
tumours [11].  
The WHO classification system also assigns each tumour type a grade of malignancy 
that is based on histopathological and molecular characteristics (Table 1). The grading 
also reflects the patients’ prognosis and has implications for their clinical management. 
Grade I corresponds to benign tumours with better prognosis, grade II and III tumours 
display features of malignant progression, while grade IV tumours are the most 
malignant and exhibit the poorest prognosis (Fig. 4) [11].  In addition to nuclear atypia 
and mitotic activity observed in lower grade tumours, the presence of microvascular 
proliferation and/or pseudopalisading necrosis is required to classify the tumour as 
grade IV (Table 1) [11, 12].  
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Table 1. The histological criteria for WHO grading of astrocytic tumours. 
Prepared based on [11]. 
Grade of 
malignancy 
Histological designation Morphological criteria 
I Pilocytic astrocytoma None 
II Diffuse astrocytoma Nuclear atypia 
III Anaplastic astrocytoma Nuclear atypia and mitotic activity 
IV Glioblastoma Nuclear atypia, mitotic activity, 
microvascular (endothelial) 
proliferation and/or necrosis 
Figure 4. Comparison of survival of patients with astrocytic brain tumours of 
different grades. Pilocytic astrocytoma (grade I), low grade astrocytoma (grade II), anaplastic 
astrocytoma (grade III) and glioblastoma (grade IV). Cum. – cumulative, MST – mean survival time. 
Reprinted with permission. Published in [13].
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1.2.2 Glioblastoma 
GBM is the most malignant brain tumour (grade IV according to WHO) [11]. It 
accounts for 12-15% of all intracranial tumours and for 54% of all gliomas. GBM is 
classified as an astrocytic tumour as it is composed mostly of neoplastic astrocytes. 
However, it is a very heterogeneous tumour and several histological variants have been 
distinguished: glioblastoma with oligodendroglioma component accounting for 12% of 
all GBMs, giant cell glioblastoma (5% of all GBMs), small cell glioblastoma and 
gliosarcoma (2% of all GBMs). GBMs may occur in the subcortical white matter of the 
cerebral hemispheres in all lobes of the brain [11]. They mostly afflict adults, and more 
frequently men than women [11]. GBM can result from successive malignant 
progression of lower grade astrocytic tumours (secondary GBM), but approximately 
85% of GBMs occur as de novo tumours (primary GBM) without a prior evidence of 
precursor lesion [11, 14]. The primary GBMs are more common in older patients, 
while secondary GBMs usually develop in younger patients [11, 14]. 
1.2.2.1 Symptoms 
There are no specific neurological symptoms associated with GBM. However, focal 
symptoms may arise, mostly as a result of elevated intracranial pressure [11] and these 
include epileptic seizures, early morning headache, nausea and vomiting [11, 15]. 
However, both intracerebral and extracerebral tumours may cause epileptic seizures. 
Moreover, differences in seizure frequencies exist between tumours of the same 
histological type indicating that tumour related epilepsy may derive its aetiology from 
several mechanisms, including tumour histological type, grade of malignancy [16], 
location, as well as, treatment modality [17], environmental and functional changes 
involving pH, neurotransmitters, such as glutamate [18], vascular and metabolic 
changes [19]. Other symptoms related to the location of the tumour may become 
apparent, such as personality changes (frontal cortex), visual disturbances (occipital 
lobe) and hemiparaplegia (motor cortex of the parietal lobe). 
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1.2.2.2 Diagnosis 
GBM is diagnosed by a combination of methods including neurological examination, 
neuroimaging involving computerised tomography (CT), magnetic resonance imaging 
(MRI) or positron emission tomography (PET) techniques, and surgical or needle 
biopsy. On T1-weighted MRI with contrast, GBM manifests as a hypo-intense lesion 
with contrast-enhanced ring structure. The hypo-intense region represents central areas 
of tissue necrosis, while the enhancing ring represents the cellularised regions 
vascularised by permeable vessels that permit leakage of contrast agent and thus 
detection of the tumour [11]. On T2-weighted and fluid-attenuated inversion recovery 
(FLAIR) images, the lesion appears hyper-intense. The GBM also tends to exhibit 
more peritumoural oedema. CT scans usually visualize ring-like contrast enhancement 
around a dark hypo-dense necrotic area [11]. The regional glucose consumption 
observed on PET scans corresponds to cellularity and is correlated with reduced 
survival [11]. On magnetic resonance spectroscopy gliomas exhibit reduced N-acetyl 
aspartate, increased choline, and decreased creatine levels [20]. Additionally, a lactate 
peak is a frequent occurrence in higher grade tumours [20]. 
However, the final diagnosis is based on histopathological examination of the 
haematoxylin and eosin stained tumour tissue obtained by stereotaxic needle biopsy or 
craniotomy followed by tumour resection. Typical histological features of GBM are: 
(1) cellular heterogeneity, (2) the presence of large, multinucleated tumour cells, (3) 
microvascular proliferation that manifests as multiple layers of endothelial cells, or 
“glomerular tufts” often located close to areas of necrosis and (4) pseudopalisading 
structures comprised of central necrotic area surrounded by apoptotic tumour cells 
[11]. 
 1.2.2.3 Molecular features of glioblastoma 
Several genetic and epigenetic aberrations characterise GBM. These aberrations result 
in the altered regulation of genes modulating the growth and survival pathways, as well 
as, the cells’ evasion from apoptosis. The most common alterations are: (1) p53 loss or 
mutation [9, 11] (2) epidermal growth factor receptor (EGFR) amplification or 
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mutation [9, 11] (3) deletion or mutation of phosphatase tensin homolog (PTEN) gene 
[9, 11] (4) MDM2 gene amplification or overexpression [9, 11] (5) platelet derived 
growth factor receptor (PDGFR) overexpression or amplification [9, 11] (6) cyclin-
dependent kinase inhibitor 2A (CDKN2A) gene alterations [9, 11] (7) isocitrate 
dehydrogenase 1 and/or 2 (IDH1 and IDH2) mutation [21].  
1.2.2.3.1 Primary vs. secondary GBM 
Numerous studies demonstrated that de novo GBMs harbour different and usually 
mutually exclusive genetic alterations from secondary GBMs that arise from 
successive malignant progression of lower grade gliomas (Fig. 5). However, there is a 
great deal of redundancy and mutations often target alternative genes of the same 
signalling pathways [9, 11].  
Primary GBMs display frequent EGFR amplification, overexpression and/or mutation 
[9, 11], Fig 5. Mutation of the EGFR gene most often results in expression of a 
receptor with ligand-independent, constitutive activity (EGFRvIII) [9, 11]. EGFR 
signalling regulates growth signals, thus its amplification or increased activity leads to 
uncontrolled progression through the cell cycle and ultimately, tumour growth. 
Amplification or overexpression of MDM2 gene is common in de novo GBMs and 
results in blocking the activity of p53 protein [9, 11], Fig 5. P53 signalling pathway 
induces apoptosis of the cell with DNA damage, therefore alterations in this control 
point lead to continued proliferation and growth of transformed cells harbouring 
multiple mutations. However, the p53 gene is usually not directly altered in de novo
GBMs [9, 11], Fig 5. Loss of p16 expression results from alterations in CDKN2A gene 
and is also more frequently altered in primary than secondary GBM [9, 11]. Lack of 
p16 protein affects retinoblastoma (RB) signalling pathway that regulates cell cycle at 
the G1/S checkpoint, allowing the tumour cells’ uncontrolled transition to S phase [9, 
11]. The alteration of PTEN tumour suppressor gene is commonly reported in primary 
GBM [9, 11]. PTEN is a phosphatase and functions as a tumour suppressor that 
negatively regulates phosphatidyl inositol 3 kinase (PI3K) activity by 
dephosphorylating phosphatidylinositol -3,4,5 trisphosphate (PIP3) to 
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phosphatidylinositol -3,4 diphosphate (PIP2) and thereby terminating PI3K signaling 
[22]. Mutations of the PTEN gene in GBMs result in elevated levels of PIP3, through 
which PI3K hyperphosphorylates PDK1/AKT resulting in enhanced survival and 
proliferation of the tumour cells [23]. 
Figure 5. Molecular features of primary vs. secondary GBM. Secondary GBM results 
from malignant progression of low grade astrocytoma characterised by frequent mutation of P53 and 
PDGF/PDGFR overexpression. Loss of heterozygosity (LOH) on chromosomes 11p and 19q and RB 
mutation is common for anaplastic astrocytoma (grade III). LOH on chromosome 10q and VEGF 
overexpression leads to progression to GBM (grade IV). In contrast to secondary GBM, the most 
frequent aberrations observed in primary GBM are EGFR overexpression, amplification and mutation, 
LOH on 10q chromosome, PTEN mutation and p16 loss. Obtained and modified from [14]. Reprinted 
with permission. 
Contrary to de novo GBM, in the secondary GBM the EGFR and MDM2 gene 
alterations are much less frequent, while p53 is commonly deleted or inactivated [9, 
11], Fig 5. Typical for secondary GBMs, is also the over-expression of PDGFR that 
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results in increased tumour cell proliferation [9, 11]. The loss of RB function is 
frequently observed in secondary GBM [9, 11]. The PTEN gene alterations also occur, 
albeit, less frequently than in primary GBM [9, 11]. The recently identified glioma 
specific mutation, IDH1/2 mutation is more common for secondary than primary GBM 
and has been proposed as a marker to distinguish the GBM subtypes [21]. The 
presence of mutated IDH1/2 is associated with prolonged patients’ survival, however, 
the role of the wild-type and mutant protein in tumour progression is not fully 
understood yet [21]. Taken together, primary and secondary GBMs display different 
patterns of genomic alterations reflecting two different mechanisms of GBM 
formation: (1) spontaneous growth of high grade tumour and (2) malignant progression 
through lower grade tumours.  
1.2.2.4 Biological behaviour of GBM  
The biology of GBM fully resembles the characteristic features of malignant tumours, 
such as aggressive growth, angiogenesis and invasion to surrounding tissue. However, 
GBM rarely metastasises outside the CNS. 
1.2.2.4.1 Proliferation 
GBM is a highly proliferative tumour as indicated by the presence of mitotic figures on 
histological examination [11]. The proliferative activity can also be measured by 
immunohistochemistry staining with antibody against Ki67 protein, that is expressed 
by actively proliferating cells but absent in resting cells. High Ki67 labelling index is 
associated with aggressive growth and it increases with the tumour grade [11]. GBM is 
characterised by high Ki67 labelling index of 15-20% compared to lower grade brain 
tumours (5-10% in anaplastic astrocytoma grade III and less than 4% in astrocytomas 
grade II) [11].  
1.2.2.4.2 Angiogenesis 
Growing tumours require nutrients, oxygen supply, and metabolic waste removal 
carried out by the blood circulation. However, with increasing size, the existing 
vasculature is insufficient and formation of new blood vessels is activated [24]. 
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Angiogenesis is one of the histological hallmarks of GBM [11]. It is triggered by up-
regulating pro-angiogenic signals induced both directly by tumour cells and also by 
stromal cells of the tumour microenvironment as a result of hypoxia occurring in the 
tumour areas with insufficient oxygen supply [9, 25]. The best characterised pro-
angiogenic factors associated with glioma are: (1) vascular endothelial growth factor 
(VEGF) [26, 27] produced by tumour, stromal and inflammatory cells and VEGF 
receptors over-expressed on glioma cells, (2) fibroblast growth factor (FGF) and FGF 
receptors up-regulated on glioma and endothelial cells [24] and (3) extracellular matrix 
(ECM) remodelling by matrix metalloproteinases (MMPs) [9, 25]. The above 
mentioned growth factors induce the angiogenic switch [28] that stimulates the 
proliferation of endothelial cells and their remodelling of ECM facilitates their 
migration and also release and activation of more pro-angiogenic factors [9, 25]. 
However, tumour-induced angiogenesis results in forming disorganised and leaky 
blood vessels as the endothelial cells associated with the tumour vasculature do not 
form proper tight junctions and tumour capillaries are often not fully covered with 
astrocytic endfeet [9].  
1.2.2.4.3 Diffuse Invasion 
The infiltration of the tumour cells into surrounding tissue is a common feature of 
GBM. Glioma cells frequently migrate along white matter tracts and through the 
corpus callosum into the contralateral hemisphere forming the so-called “butterfly 
glioma” [11]. GBM cells often invade also other parts of the brain and form new 
lesions [11]. The highly invasive nature of GBM also results in the occurrence of 
recurrent tumours arising from neoplastic cells remaining in adjacent tissue after the 
tumour resection. However, invasion into the subarachnoidal space, infiltration into the 
blood vessels and subsequent metastases outside the brain occur very rarely [11].  
1.2.2.5 Current standard treatment of GBM 
Routinely, therapy is initiated with administration of steroids, such as dexamethasone 
(decadron) 4 mg pre-operatively the morning prior to surgery to reduce oedema and 
inflammation. However, if the patient presents with oedema, decadron may be 
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administered for the clinical management but it is tailored for each patient and assessed 
on a regular basis due to potential side effects. Furthermore anticonvulsant medication 
may be administered for the management of epileptic seizures when required. The 
current standard treatment for GBM patients includes surgery followed by concomitant 
chemo- and radiotherapy. The efficiency of surgical resection depends on the location 
of the tumour, however, the principle is to remove as much of the tumour bulk and 
associated tissue as possible without affecting the brain functionality [15]. 
Nevertheless, due to the highly invasive and infiltrative nature of GBM, residual 
tumour cells are inevitable, both in the adjacent resection margins and very often in the 
distant brain parenchyma. Therefore, 3-6 weeks post subtotal-surgery patients are 
administered concurrent ionising radiotherapy with chemotherapy depending on their 
performance status measured by the Karnofsky score [29]. External beam radiation is 
administered as fractionated doses of 2Gy daily, 5 days a week for 6 weeks, achieving 
a total 60Gy dose [30]. The major aim of this treatment is to induce double-strand 
break (DSBs), that is the most toxic form of DNA damage for the cell [9]. The DNA 
damage results in apoptosis or cell cycle arrest [9]. The chemotherapy is given during 
the course of radiotherapy in order to induce maximal DNA damage [30]. To date, 
temozolomide™ (TMZ) is the most efficient drug for GBM patients [31]. The standard 
protocol of TMZ administration is 75mg per square meter of body-surface area 
(mg/m2) daily, 7 days per week during the course of radiotherapy [31]. Four weeks 
after the chemotherapy is completed, patients are given up to 6 cycles of adjuvant TMZ 
treatment at a dose of 150-200 mg/m2 daily for 5 days every 28-day cycle [31]. TMZ is 
an orally administered pro-drug that is metabolised to 3-methyl-(triazen-1-
yl)imidazole-4-carboxamide (MTIC) [30]. MTIC induces DNA damage by methylation 
at different positions, however, N7-guanine and N3-adenine being most frequent, 
while methylation of O6-guanine is the most significant for the anti-tumour effect of 
TMZ [30]. An important predictive factor for patients’ clinical response to TMZ is the 
methylation status of O6-methylguanin DNA methyltransferase (MGMT) gene 
promoter [30]. MGMT is an enzyme broadly expressed by normal and neoplastic 
tissues, however, the promoter of the MGMT gene is often hypermethylated in tumour 
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tissue [30]. MGMT repairs O6-guanine methylation induced by TMZ, thus silencing its 
gene expression is associated with better efficiency of TMZ treatment [30].  
1.2.2.6 Prognostic and predictive factors 
Prognostic factors are patient’s characteristics that are associated with their prognosis 
independently of the treatment received. Predictive factors are features associated with 
patient’s response to specific treatment.  
Important established prognostic factors in GBM are patient’s age at diagnosis, 
patient’s performance status measured by the Karnofsky scale and neurological 
function [32]. Younger patients (<50 years) and those with better performance status 
and intact neurological functions tend to survive longer [32]. Moreover, radical tumour 
resection is also associated with better prognosis [32]. Prolonged survival was also 
observed in GBM patients with IDH1 mutation compared to those without this 
mutation [21]. As mentioned above, the methylation status of MGMT gene promoter 
predicts clinical response to TMZ treatment, however, it has also been demonstrated to 
be a prognostic factor [33]. However, all GBM patients receive the standard treatment 
including TMZ regardless of the methylation status of MGMT gene promoter.  
1.3 Brain immunology 
For a long time, the brain was considered as an immune-privileged organ and several 
lines of observations supported this dogma. The lack of immune surveillance was 
postulated due to the presence of the blood brain barrier (BBB), lack of lymphatic 
drainage, low levels of major histocompatibility complex (MHC) expression required 
for antigen presentation and low numbers of professional antigen presenting cells 
(APCs). On the other hand, occurrence of autoimmune diseases and inflammation 
within the brain suggests that the brain is not fully protected from the immune system. 
Indeed, it is established that activated immune cells are able to traverse the BBB [3] 
and enter the brain with cerebrospinal fluid (CSF) circulation [34]. Moreover, 
microglia have been shown to express MHC class II and perform immune functions 
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similar to macrophages [35]. Therefore, microglia are considered the brain resident 
antigen presenting cells (APCs). In addition, the central nervous system (CNS) 
antigens can be transported to the deep cervical lymph nodes with CSF flux via the 
nasal mucosa and afferent lymphatics [34]. The fact that the immune system has access 
to the brain and furthermore, that the BBB is variably disrupted at the brain tumour 
site, implies that anti-tumour immune responses can potentially occur in brain cancers. 
This perspective opens the possibility of developing an immunotherapy for brain 
tumour patients. 
1.3.1 Blood – brain barrier and blood – cerebrospinal fluid barrier 
The BBB is a physical barrier between the brain and peripheral blood circulation. The 
physiological functions of the BBB are (1) to protect the brain against infectious and 
toxic agents that could potentially enter the brain via blood circulation (2) to regulate 
the supply of nutrients and metabolic waste removal and (3) to maintain homeostasis 
[9]. The BBB is composed of endothelial cells (ECs) at the lumen of blood vessels, 
perivascular pericytes covered with basal lamina and further supported by astrocytes’ 
end-feet (Fig. 6) [9].  
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Figure 6. The structure of blood – brain barrier (BBB). The BBB is formed by 
endothelial cells connected by tight junctions and covered with basement membrane. Pericytes and 
astrocyte endfeet further support the BBB structure. Reprinted with permission. Published in [36].
The ECs of brain capillaries are continuously connected to each other by tight 
junctions, they lack fenestrae and have limited vesicles for pinocytosis (Fig. 6). These 
features mainly contribute to reduced permeability of the cerebral vasculature [9]. 
Nutrient uptake is carried out by selective molecular carriers and the ion passage is 
maintained by ion transporters [9]. Pericytes can further support the BBB function by 
their capability to phagocytose the molecules that manage to cross the endothelial wall 
[9]. The basal lamina is composed of collagen, fibronectin and heparin sulphate 
proteoglycans produced by ECs and astrocytes [9]. The extracellular matrix 
components that are unique for brain vasculature are laminin 1 and 2 [9]. Astrocyte 
end-feet cover the surface of brain blood vessels and capillaries, maintaining the high 
electrical resistance tight junctions in ECs (Fig. 6) [9]. Perivascular macrophages 
(PMV) also play important roles in the regulation of permeability of the brain 
microvessels and at the boundary of arterioles and capillaries, but they are absent in 
brain capillaries [9]. They are able to phagocytose pathogens and macromolecules and 
they contribute to the regulation of cellular trafficking across the BBB [9]. In contrast 
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to the BBB, the blood – cerebrospinal fluid barrier (BCSFB) is based on the tight 
junctions formed by choroid plexus epithelium while the endothelial cells of BCSFB 
lack the tight junctions (Fig. 7) [37]. Due to the fenestrated endothelium as well as 
absence of astrocyte end-feet and pericytes, the BCSFB is more permeable than the 
BBB (Fig. 7).  
Figure 7. The structure of blood – cerebrospinal fluid barrier (BCSFB). The BCSFB 
is maintained by tight junctions connecting the epithelial cells of choroid plexus. The endothelial cells 
forming the vessel wall of choroid plexus capillaries do not form tight junctions and are fenestrated. 
The transport across the BCSFB is maintained by molecular transporters such as multidrug resistance-
associated protein 1 (MRP1) and P-glycoprotein (Pgp). Reprinted with permission. Published in [38].
1.3.2 Immune surveillance in the central nervous system 
Despite the presence of the BBB and BCSFB, under physiological conditions the CNS 
is under constant immune surveillance and active immune response can be triggered in 
various pathological conditions like infection, injury, as well as autoimmune disease. 
Even though there is no lymphatic drainage in the CNS, the CSF produced in the 
choroid plexus and circulating within the subarachnoid space (SAS) might be 
considered as an equivalent of lymph [34]. The CSF is reabsorbed at the arachnoid villi 
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into the venous blood, however, CSF draining along the cranial and spinal nerves can 
also reach the lymph nodes, e.g. deep cervical lymph node (Fig. 8) [34].  
Figure 8. CSF circulation in the CNS and drainage to deep cervical lymph node.
CSF is produced by the choroid plexus in the ventricle, circulates within subarachnoid space (SAS) 
and most of it is reabsorbed to blood via arachnoid villi. However, part of the CFS can carry the CNS-
derived antigens into the deep cervical lymph node via afferent lymphatics along olfactory nerve. 
Reprinted with permission. Published in [34].
Therefore, CSF is a carrier of CNS – derived soluble antigens that enter the CSF 
circulation with the interstitial fluid from brain parenchyma [34]. Once entered the 
CSF, these antigens can be sampled by meningeal and choroid plexus macrophages or 
delivered to lymph nodes [34]. Moreover, CNS is patrolled by peripheral immune cells 
that enter the CSF via the choroid plexus [34]. The major cellular component (more 
than 90% of all cells) of CSF is memory T cells, predominantly CD4+ T cells [34, 39]. 
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Other immune cells detected in the CSF of healthy brain are B cells, NK cells, 
dendritic cells (DCs), monocytes and naïve T cells [34, 39].  
Under normal physiological conditions the only immune cells present in the brain 
parenchyma are microglia [34]. However, it has been demonstrated that T cells and B 
cells activated upon various pathological conditions are able to cross the BBB and 
access the brain directly from the blood vessels and capillaries (Fig. 9) [3, 34].  
Figure 9. Leukocyte trafficking across the BBB.  
The attachment of rolling activated leukocytes is mediated by interactions of adhesion 
molecules (ICAM-1) and integrins (LFA-1). Further signalling with adhesion 
molecules, integrins and selectins is required for diapedesis into perivascular space 
(e.g. interaction of CXCR4 with CXCL12). Migration across the glia limitans is 
facilitated by further positive signals from CNS parenchyma, including chemokines. 
However, high concentration of CXCL10 causes retention of immune cells within the 
perivascular space. Reprinted with permission. Published in [3] 
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The immune cell trafficking across both BBB and BCSFB is initiated by rolling along 
the vessel wall, adhesion and diapedesis across the vascular endothelium and is 
followed by migration across the glia limitans (basal membrane and astrocyte end-feet) 
into the brain parenchyma (Fig. 9). Alternatively, the cells may enter the CSF across 
the choroid plexus epithelium (Fig. 10) [3]. These processes require expression of 
several adhesion molecules, integrins, selectins, chemokines and their receptors [3]. 
However, the exact molecular mechanism of immune cell trafficking in the CNS has 
not yet been fully resolved.   
Figure 10. Leukocyte trafficking across the BCSFB. 
Microglia are the only resident immune cells within the brain parenchyma. They are 
cells of myeloid origin that, besides supporting neurons’ functionality, perform also 
functions similar to tissue specific macrophages [35, 40, 41]. They are able to 
phagocyte the debris and dead cells occurring in the CNS [40]. They constitutively 
express MHC class II molecules and they perform constant surveillance of the 
extracellular space, thus they can sample and present antigens [40]. Upon activation, 
they can also secrete cytokines such as tumour necrosis factor (TNF), interferon 
Activated leukocytes 
undergo rolling and 
adhesion to the vessel wall 
mediated by integrins and 
adhesion molecules. After 
crossing the fenestrated 
endothelium, they migrate 
to choroid plexus 
epithelium attracted by 
chemokines (CCL19, 
CCL20) expressed on the 
basolateral side of the 
epithelial cells and enter 
the CSF in the ventricle. 
Reprinted with permission. 
Published in [3] 
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gamma (IFNȖ), interleukin (IL)-1 and chemokines to recruit other immune cells to the 
site of infection or injury [35]. Moreover, microglia are also able to respond to certain 
infections, for example they can recognise bacterial lipopolysaccharide [35]. Therefore 
they serve as a first line immune defence in the CNS. Astrocytes and other glial cells 
have also been shown to contribute to brain immunity by producing various cytokines 
and chemokines [40].  
1.3.3 The immune status of glioblastoma patients 
As described above, under physiological conditions parenchymal microglia, 
meningeal, choroid plexus and perivascular macrophages and T cells circulating in the 
CSF patrol the CNS. Thus, the anti-tumour immune response can be potentially 
triggered in the brain cancer, including GBM patients. On the other hand, GBM 
develops multiple mechanisms of immune escape. Moreover, the standard treatment 
can also contribute to GBM patients’ immune suppression. Novel adjuvant 
immunotherapies hold a promise of improving the patients’ outcome by stimulating the 
anti-tumour immune response and/or targeting tumour immune escape and 
immunosuppressive mechanisms. However, for developing immune-based treatment it 
is of great importance to investigate the immune status of GBM patients.  
An interesting concept of cancer immunoediting emerged recently [42]. In this 
concept, the interactions of immune system with tumour can be divided into three 
major steps (Fig. 11). At the early stage of cancer development, the immune system 
eliminates susceptible tumour cells (elimination) that leads to selection of immune-
resistant cells (equilibrium) and further to develop immune escape and 
immunosuppressive mechanism (escape) [42].  
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Figure 11. The concept of cancer immunoediting. The immune cells eliminate susceptible 
tumour cells (elimination) that leads to selection of immune-resistant cells (equilibrium) that further 
develop immune escape and immunosuppressive mechanisms (escape). Reprinted with permission. 
Published in [43]. 
This concept seems to fit also GBM and potentially has implications for the efficiency 
of immunotherapies [43]. For example, GBM treated with targeted therapies based on 
single tumour associated antigen, like anti-VEGF or anti-EGFRvIII treatments, after 
initial regression due to the clearance of treatment-susceptible cells (elimination) may 
relapse due to selection of resistant cells (equilibrium) and develop alternative 
signalling pathways and/or resistance to immune mediated killing (escape) in case of 
immune-stimulating therapies, like therapeutic antibodies and vaccines [43]. 
1.3.3.1 Immune cell populations infiltrating the brain tumours 
1.3.3.1.1 Macrophages/microglia 
Brain resident microglia together with infiltrating macrophages are the major immune 
cell population within GBM microenvironment and comprise approximately one third 
of all cells in the tumour tissue [44, 45]. There is no specific marker that could be used 
to distinguish microglia from macrophages histologically but most flow cytometry 
based studies define microglia and macrophages as CD11b+CD45low and 
CD11b+CD45high populations, respectively [46]. Both microglia and macrophages can 
represent two functionally different activation states depending upon exposure to 
37
specific stimuli and environmental conditions. Stimulation with pro-inflammatory 
cytokines such as IFNȖ, TNF and recognition of pathogens induce  the so-called M1 
phenotype (classically activated), while anti-inflammatory cytokines like IL-4, IL-13 
and IL-10 induce M2 type (alternatively activated) macrophages/microglia [47, 48]. 
The M1 type macrophages/microglia are important for removal of pathogens, antigen 
presentation and stimulation of T cell responses [47, 48]. They up-regulate co-
stimulatory molecules CD80 and CD86, MHC class II and toll-like receptors 2 and 4 
(TLR2 and TLR4) and produce pro-inflammatory cytokines such as IFNȖ, TNFĮ, IL-
12 and IL-23 [47, 48].  
On the other hand, M2 type macrophages/microglia have less antigen presenting 
capacity and are involved in tissue repair and immune modulation by producing anti-
inflammatory cytokines like IL-10 and TGFȕ [47, 48]. Phenotypically, they are 
characterised by up-regulation of mannose receptor (CD206) and scavenger receptors 
CD163 and CD204 and decreased expression of co-stimulatory molecules CD80 and 
CD86 [47, 48]. The polarization of macrophages/microglia into M1 and M2 type is 
considered to have implications in various pathological conditions, including brain 
tumours [47]. It is believed that M1 type macrophages/microglia can potentially 
mediate anti-tumour activity, while M2 type macrophages/microglia have been 
demonstrated to support glioma progression [45, 46]. The tumour-supporting M2 type 
macrophages/microglia seem to be the predominating immune cell population within 
the tumour microenvironment as a result of glioma – mediated recruitment and 
immunomodulation [46].  
1.3.3.1.2 Lymphocytes 
A number of studies demonstrated T cell infiltration of both CD4+ and CD8+
phenotype in GBM [49-53]. The degree of T cell infiltration and their distribution 
within the tumour tissue varied between patients [50-52]. Tumour infiltrating T cells 
were usually grouped around blood vessels, necrotic areas, with single cells scattered 
in the tumour parenchyma [50, 51]. Most of the recent investigations reported that the 
increased number of T cells within the tumour microenvironment correlates with 
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longer survival of GBM patients [49, 50, 53, 54]. Several studies evaluated the 
functional status of tumour infiltrating T cells. Some of them demonstrated that T cells 
isolated from GBM biopsies and cultured ex-vivo were capable of lysing autologous 
tumour cells [55, 56]. However, such experimental conditions do not fully reflect the in 
situ situation, as T cells might be activated upon ex-vivo culture conditions. One study 
showed that tumour infiltrating T cells express granzyme B and establish 
immunological synapses upon contact with GBM cells. This suggested that T cell – 
mediated anti-tumour immune response occurs in GBM [57].  
Detailed phenotyping of tumour infiltrating lymphocytes revealed the presence of T 
regulatory cells (Tregs) of CD4+CD25highFoxp3+ phenotype within the tumour 
microenvironment. Tregs are implicated in T cell suppression [58], however, there is 
currently no consensus regarding their prognostic significance in GBM patients [59, 
60].  
Several studies investigated B cell [51, 61] and NK cell [51, 57, 61, 62] infiltration in 
GBM, but those lymphocyte subsets were either absent or constituted minor immune 
cell populations within the tumour microenvironment. However, as discussed in Paper 
II, the methodology used in those studies was not sufficient for specific NK cell 
detection.   
1.3.3.2 Glioma – induced immunosuppression 
Numerous observations indicate that GBM patients are immunosuppressed both locally 
at the tumour site, and at the systemic level. It has been postulated that this 
immunosuppression is, at least, partially induced by the cancer cells [63]. In addition to 
lymphopenia, systemic immunosuppression of GBM patients manifests also in 
impaired function of peripheral lymphocytes, such as decreased proliferation in 
response to various mitogens, cytokine production [63] and cytotoxic activity [64]. 
Peripheral blood monocytes down-regulate the expression of MHC class II molecules, 
resulting in their reduced ability of antigen presentation [63]. Moreover, the cytokine 
balance in GBM patients is shifted in favour of anti-inflammatory and immune-
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modulating T helper 2-type responses [63] that are characterised by stimulation of the 
humoral response (e.g. B cell activation and antibody production) and inhibition of the 
pro-inflammatory Th1 response [65]. Glioma is also believed to preferentially recruit 
and/or induce immune cell subsets of tumour-supporting, immune-tolerizing and 
immune suppressive properties, such as M2 type macrophages and microglia or T 
[46, 60]. The best known immunosuppressive factors secreted by glioma are 
transforming growth factor-beta (TGFȕ), prostaglandin E2 (PGE2) and IL-10 [66]. 
TGFȕ suppresses T cell activation and proliferation and CTLs’ function by down-
regulating the expression of FasL, and the production of granzymes, perforin and IFNȖ
[66]. Glioma – derived TGFȕ has been also shown to suppress NK cells by down-
regulating the expression of the NK cell activating receptor NKG2D [67]. PGE2 
mediates decreased secretion of T 1 type cytokines and increased production of T 2 h
type cytokines and it inhibits anti-tumour activity of T cells and NK cells and enhances 
activity of Tregs [66]. IL-10 is a Th2 type cytokine that down-regulates T cell 
proliferation and activation and MHC class II expression on APCs [66]. 
1.3.3.3 The impact of treatment on the immune system of GBM patients 
The GBM patients’ immunosuppression is not only a result of glioma – derived 
factors, but also a side effect of chemo- and radiotherapy. It has been observed that 
brain tumour patients treated with steroids are immunocompromised and at increased 
risk of infection [68, 69]. Temozolomide has also been demonstrated to induce 
immunosuppression of GBM patients that is associated with reduced lymphocyte 
count, reduced numbers of CD3+, CD4+, CD8+CD56+ T cells, NK cells, B cells and an 
increased proportion of CD4+CD25+Foxp3+ Tregs [70].  
1.4 Natural Killer cells 
Natural killer (NK) cells are large granular lymphocytes of the innate immune system 
that account for approximately 5-15% of the lymphocytes in peripheral blood [65]. 




cells, therefore, they belong to the lymphocyte family [65]. NK cells are larger in size 
and are more granular than T cells and B cells [65]. They play important roles in viral 
infections and anti-tumour immunity [65, 71]. Due to their ability to recognise and 
directly lyse the virus-infected or transformed cells without prior sensitisation or co-
stimulation, NK cells are considered as components of the innate immune system [71]. 
They do not express T cell receptors [71] thus, they are phenotypically characterised as 
CD3 negative CD56 positive lymphocytes. NKp46 receptor expression is also 
commonly used as a marker of NK cells [72]. NK cells can be subdivided into two 
functionally distinct subsets based on the expression level of CD56 [73]. In the 
peripheral blood, under steady state conditions, the main population are CD56dim NK 
cells that are considered more cytotoxic [73]. The minor subset of CD56bright NK cells 
are more involved in cytokine and chemokine secretion [73]. Most NK cells also 
express FcȖRIIIA receptor (CD16) that in combination with the CD56 expression level 
may serve for further sub-classification of NK cells [74]. 
1.4.1 Target cell recognition 
NK cells express a variety of receptors on their surface that allows them to distinguish 
normal cells from transformed or virus infected cells. Upon binding their ligands, these 
receptors transduce activating or inhibitory signals and the overall balance determines 
whether the NK cell will recognise an encountered cell as a target to kill or will remain 
tolerant.  
1.4.1.1 Killer Immunoglobulin-like Receptors  
Killer Immunoglobulin-like Receptors (KIR) belong to the immunoglobulin (Ig) 
superfamily and recognise MHC class I motifs expressed on all nucleated self-cells. 
The nomenclature is based on their structure that determines also their activating or 
inhibitory function. KIRs contain two or three Ig-like domains in their extracellular 
part (KIR2D and KIR3D, respectively), a transmembrane domain and a long-tailed 
(KIR2DL and KIR3DL inhibitory receptors) or short-tailed (KIR2DS and KIR3DS 
activating receptors) cytoplasmic domain [75]. The long-tailed cytoplasmic domains 
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possess immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that are critical for 
transducing inhibitory signals [75]. The short-tailed cytoplasmic domain mediates 
activating signals through interaction with DAP12 adaptor protein containing 
immunoreceptor tyrosine-based activation motif (ITAM) [75]. The KIRs recognise 
different allelic variants of human leucocyte antigen-A (HLA-A), HLA-B and HLA-C 
molecules (Table 2). KIR2DL1, KIR2DS1 and KIR2DS4 interact with HLA-C2 group 
containing Lysine residues at position 80 in the Į1-domain of the HLA heavy chain 
[76]. KIR2DL2, KIR2DL3 and KIR2DS3 bind HLA-C1 group with Asparagine at 
position 80 in the Į1-domain of the HLA heavy chain [76, 77]. KIR3DL1 recognises 
HLA molecules with Bw4 epitope, while KIR3DL2 ligands are HLA-A3 and HLA-
A11 [76, 78, 79]. Ligands for KIR3DL3, KIR2DL5, KIR2DS2, KIR2DS3, KIR2DS5 
and KIR3DS1 remain unknown [76].  
Table 2. KIR receptors and their HLA ligands. Prepared based on published 
literature [76]. 
KIR receptor HLA ligand 
Inhibitory 
receptors 
KIR2DL1 HLA-C2 group 
KIR2DL2 HLA-C1 group 















∞ can mediate also activating signals 
Exceptional among KIR receptors is KIR2DL4. In contrast to other KIRs, it recognises 
a non-classical HLA ligand, HLA-G and it is constitutively expressed by all NK cells 
[80]. Even though it contains a long-tailed cytoplasmic domain with ITIM, KIR2DL4 
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can mediate both inhibitory and activating signal [80]. Although some activating KIR 
recognise the same HLA motifs as their inhibitory homologues (for example KIR2DS1 
and KIR2DL1), they are considered to bind the ligands with lower affinity [81]. Due to 
high polymorphism of KIR genes, NK cells from different individuals express 
different repertoires of KIR receptors. However, based on the genotype, two main 
haplotype groups can be distinguished [82]. The haplotype A contains KIR2DL1, 
KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3 and KIR2DS4, while the 
haplotype B has been defined as containing more than one activating KIR gene [82]. 
Inhibitory KIRs are essential for distinguishing self cells from non-self cells. The 
function of activating KIRs has not been fully understood yet.  
1.4.1.2 Natural cytotoxicity receptors  
Natural cytotoxicity receptors (NCR): NKp30, NKp44 and NKp46 belong to the Ig 
superfamily and are essential for NK cell activation. NCR-mediated activating 
signalling requires an association of the receptor with an adaptor protein containing 
ITAM [83]. NKp30 is constitutively expressed on NK cells and among other ligands, it 
recognises tumour antigens B7-H6 (expressed on leukemias, lymphomas, carcinomas, 
melanomas [84]) and BAG6 [83]. NKp44 is expressed only on activated NK cells and 
plays an important role in immune responses to viral and bacterial infections [83]. 
NKp46 is considered as the most reliable marker of NK cells. It binds viral 
haemagglutinin (HA) and HA-neuraminidase (HN) and tumour-associated ligands 
[83]. Although NCRs are in general considered as activating receptors, in some cases 
binding their ligands inhibits the activating signal transduction. For example, binding 
the pp65 protein expressed on human cytomegalovirus (HCMV) infected cells to 
NKp30 disrupts the interaction of NKp30 with the adaptor protein CD3ȗ that is 
essential for transducing the activating signal [83]. Although not all the ligands for 
NCRs have been identified, their expression on tumour and infected cells has been 
demonstrated by using fusion proteins [85] and the role of the NCRs has been proven 
in cytotoxicity experiments by blocking the receptor-ligand interactions [85, 86]. 
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1.4.1.3 Natural killer group 2 receptors 
Natural killer group 2 (NKG2) receptors belong to the C-type lectin-like receptor 
superfamily expressed on the majority of NK cells and a proportion of cytotoxic T 
lymphocytes (CTLs) [87]. All of them, except NKG2D, form heterodimer complexes 
with CD94 and recognise the non-classical MHC class I molecule, HLA-E [87]. 
NKG2A and NKG2B have two ITIMs in their cytoplasmic domains and transduce 
inhibitory signals [87]. NKG2C, NKG2E and NKG2H lack ITIMs and interact with the 
DAP12 adaptor protein containing ITAM, and thus mediate activating signal [87]. 
NKG2E binds HLA-E with the same affinity as NKG2A, while NKG2C binds the 
ligand with much lower affinity [87]. NKG2 receptors play a role in the regulation of 
NK cell function. The interaction of NKG2A with HLA-E has also been postulated as 
a mechanism of modulating the adaptive immunity [88]. NKG2D differs from the other 
members of the NKG2 group. It is expressed by the majority of NK cells and CTLs as 
homodimer in association with adaptor protein DAP10 [89]. NKG2D is an activating 
receptor and recognizes a variety of ligands expressed on transformed, infected or 
stressed cells. These ligands are MHC class I – related chains A and B (MICA and 
MICB) and UL16 binding proteins (ULBPs) [90] and under physiological conditions, 
they are not expressed by normal, healthy cells, or are expressed at very low levels. 
Therefore, NKG2D, in addition to NCRs, is essential in recognising transformed and 
infected cells expressing normal levels of MHC class I molecules.  
1.4.1.4 NK cell signalling pathway 
The interaction of NK cell activating receptors with ITAM bearing adaptor proteins 
(DAP12, CD3ȗ, FcRȖ) initiates a signalling cascade resulting in cytokine release 
and/or secretion of lytic granules. First, ITAM proteins are phosphorylated by the Src 
family of protein tyrosine kinases (PTKs) that results in activation of the Syk family of 
PTKs (Fig. 12) [91, 92]. This in turn, leads to activation of NK cell cytotoxicity 
pathway involving the phosphatidylinositol 3-kinase (PI3K) – Akt pathway and the 
mitogen-activated protein kinase (MAPK) pathway (Fig. 12) [91, 92]. The NKG2D 
receptor associated with DAP10 induces similar signalling cascade, however, DAP10-
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mediated NK cell activation is independent from the Syk family of PTK [91, 92]. 
Another major difference is that NKG2D-mediated activation alone is not sufficient to 
trigger cytokine release, while ITAM-induced signalling results in both cytotoxicity 
and cytokine secretion [91].  
Figure 12. NK cell signalling pathways. Activating receptors (blue and green) associate with 
adaptor proteins (blue and green) and initiate signalling cascade (arrows) leading to secretion of 
cytolytic granules and cytokines. The inhibitory receptors (red) activate phosphatases SHP-1 and 
SHP-2 that inhibit the activating signal (dashed lines) by dephosphorylation of various signal 
transducers. Reprinted with permission. Published in [91]. 
On the other hand, binding of ligands to NK cell inhibitory receptors bearing ITIM 
domains results in tyrosine phosphorylation of ITIMs and recruitment of protein 
tyrosine phosphatases SHP-1 and SHP-2 (Fig. 12) [91]. They inhibit NK cell activation 
by dephosphorylating proteins involved in down-stream ITAM- and DAP10-mediated 
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signalling, like Vav and SLP-76 proteins (Fig. 12) [91, 92]. Therefore, the overall 
balance between phosphorylation induced by activating signals and dephosphorylation 
of the same substrates initiated by inhibitory signals determines the triggering of NK 
cell cytotoxicity and cytokine release.  
1.4.2 Direct cellular cytotoxicity 
Upon recognition of target cells, if the activating signals override the inhibitory 
signals, NK cells are triggered to perform their cytotoxic functions. The two major 
mechanisms that mediate NK cell – dependent killing are: (1) secretion of cytotoxic 
granules (2) inducing apoptosis via death receptors (Fig. 13) [93]. NK cells 
constitutively express perforin and granzymes that are encapsulated in lytic granules in 
the cytoplasm [94]. Upon activation, NK cells form an immunological synapse with the 
target cell and rearrange their cytoskeleton to facilitate trafficking of the lysosomes 
towards the site of the synapse [94]. Exocytosis of the lysosomes results in release of 
the lytic granules towards the target cell [94]. Perforin forms pores in the cytoplasmic 
membrane of the target cells and enables the entry of granzymes into the cytosol [94]. 
Granzymes are serine proteases that are capable of inducing both classical apoptosis 
and caspase-independent cell death [95]. Granzyme A and Granzyme B are the most 
abundantly expressed and best described among granzymes. Granzyme B cleaves 
caspases and their substrates, while Granzyme A induces DNA damage by single-
stranded nicks [95]. Multiple mechanisms of inducing cell death by granzymes enable 
the elimination of apoptosis-resistant cells. 
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Figure 13. Mechanisms of NK cell – mediated cytotoxicity. (a) secretion of cytotoxic 
granules and (b) apoptosis induced by interactions of death receptors with their ligands. Reprinted 
with permission. Published in [93].
NK cells express also ligands for death receptors – Fas Ligand (CD95L, CD178), 
tumour necrosis factor (TNF) and TNF-related apoptosis inducing ligand (TRAIL) 
[93]. Binding ligands to death receptors - Fas (CD95) or TNF receptor - leads to 
apoptosis of the receptor-bearing cell (Fig. 13) [93]. Therefore, efficiency of Fas 
Ligand- or TNF- mediated NK cell cytotoxicity is dependent on the level of death 
receptors expressed on target cells and their inherent susceptibility or resistance to 
apoptosis. 
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1.4.3 Antibody dependent cellular cytotoxicity 
NK cells are able to recognize and kill cells coated with antibodies through a process 
called antibody dependent cellular cytotoxicity (ADCC). It is initiated by binding of 
the Fc part of antibody to the FcȖRIIIA (CD16) receptor expressed on the majority of 
NK cells. CD16 recognises antibodies of IgG class. Upon binding its ligand, CD16 
activates NK cell - mediated cytotoxicity and cytokine secretion [91]. CD16 interacts 
with ITAM-bearing adaptor proteins CD3ȗ and FcRȖ transducing activating signals in 
a manner similar to the other NK cell activating receptors [91]. This process plays an 
important role in enhancing the adaptive immune response.   
1.4.4 Cytokine and chemokine secretion 
NK cells secrete a variety of cytokines, pro-inflammatory such as IFNȖ, anti-
inflammatory, including IL-5, IL-10, IL-13 and growth factors, such as granulocyte 
colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating 
factor (GM-CSF) [71, 93]. Among them, IFNȖ has attracted most attention due to its 
multiple immune-stimulatory properties. IFNȖ is a pro-inflammatory cytokine that 
promotes T-helper 1- (Th1) type responses and stimulates effector lymphocytes – NK 
cells and CTLs [93]. Moreover, IFNȖ also activates the innate immune cells, for 
example by up-regulating MHC class I and II and expression of co-stimulatory 
molecules on macrophages [93]. NK cells also mediate the recruitment of other 
immune cells into the site of inflammation by secreting various chemokines, such as 
monocyte chemotactic protein – 1 (MCP-1, CCL2), macrophage inflammatory protein 
1-Į (MIP1-Į, CCL3), macrophage inflammatory protein 1-ȕ (MIP1-ȕ, CCL4) and 
regulated on activation normal T cell expressed and secreted (RANTES, CCL5) [71]. 
1.4.5 Tolerance to normal cells 
The tolerance to self, healthy cells is maintained mainly by two factors occurring at the 
same time: (1) interactions of inhibitory KIR receptors expressed on NK cells and their 
ligands, HLA class I molecules expressed on each somatic cell, and (2) lack of or very 
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low expression of pathogen-specific or stress-induced antigens that are ligands for 
activating NK cell receptors (Fig. 14). However, KIR receptors are inherited 
independently from HLA molecules and due to high polymorphism of both KIR and 
HLA genes, it may potentially occur that some NK cells express receptors that do not 
recognize self-ligands and these NK cells may be autoreactive to normal cells [96]. 
However, these NK cells remain hyporesponsive and do not cause autoimmunity. Yet, 
they can be activated upon infection or inflammation by cytokines like IL-2 and IL-12 
[96]. The mechanism mediating tolerance of NK cells missing inhibitory KIRs for self 
MHC class I ligands has not been fully understood yet. So far, there is no evidence of 
negative or positive selection of NK cells taking place in the bone marrow during NK 
cell development or in the periphery [96]. One hypothesis postulates that to become 
functional effector cells, NK cells require “licensing” that is mediated by interaction of 
inhibitory KIR with its specific ligand [96]. The opposite hypothesis suggests that fully 
functional NK cells become anergic under chronic stimulation in the absence of 
inhibitory signals mediated by inhibitory KIRs [96]. Another model proposed that NK 
cell potency is determined by the number of inhibitory KIRs expressed and their 
affinity to self ligands [96]. The interaction of NKG2A receptor with HLA-E plays 
also an important role in NK cell regulation and self-tolerance. However, further 
studies are needed to fully resolve the mechanism of NK cell self-tolerance.  
1.4.6 NK cells in tumour surveillance and anti-cancer therapy 
Due to their above described physiological functions, NK cells play an important role 
in anti-cancer immunity. In various types of cancers NK cells have been demonstrated 
to perform surveillance and contribute to the anti-tumour immune response [93, 97]. In 
haematological malignancies, haploidentical allogeneic NK cells have been shown to 
mediate Graft versus Leukemia (GvL) effect and protect patients receiving 
haematopoietic stem cell transfer (HSCT) against Graft vs. Host Disease (GvHD) [98]. 
Moreover, numerous studies reported prognostic significance of endogenous NK cell 
tumour infiltration and activity in various solid tumours [99-103]. NK cells are also 
considered to play an important role in controlling metastasis [101]. The anti-tumour 
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response mediated by endogenous NK cells occurs due to the “missing self” and/or 
“induced self” mechanisms, while in allogeneic settings the KIR-HLA mismatch is 
considered to play an essential role.  
1.4.6.1 “Missing self” and “induced self” hypothesis 
As mentioned above, NK cells discriminate between self and non-self cells by 
recognising HLA class I molecules expressed on all healthy somatic cells. In the 
absence of ligands for activating receptors, binding of HLA to inhibitory KIR receptors 
keeps NK cells tolerant. Tumour cells often down-regulate the expression of HLA in 
order to avoid destruction from CTLs. However, such cells are recognised by NK cells 
as non-self due to the lack of HLA expression (Fig 14). On the other hand, some 
transformed cells express HLA at normal levels. Those cells can be eliminated due to 
the “induced self” mechanism (Fig. 14) [71, 93, 104]. Tumour cells frequently over-
express on their surface stress-induced molecules that are recognised by the NK cell 
activating receptor NKG2D, thus the activating signal overrides the inhibitory signal 
mediated by the KIR-HLA interaction. 
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Figure 14. NK cell tolerance of normal cells and 
recognition of tumour cells via “missing self” and 
“induced self” mechanisms.
1.4.6.2 The KIR – HLA mismatch 
The term “KIR - HLA mismatch” refers to an approach, so far, mainly in HSCT for 
leukaemia patients [98]. The genes encoding HLA molecules are very polymorphic and 
different individuals express different allelic variants of HLA. This is one of the 
(a) Healthy cells express MHC 
class I molecules recognised by 
inhibitory KIRs expressed on 
NK cells and do not express 
activating ligands for NK cell 
at sufficient level, thus NK 
cells remain tolerant. (b) NK 
cells recognise tumour cells 
that down-regulate MHC class I 
expression due to “missing 
self” mechanism. (c) Tumour 
cells often up-regulate stress-
induced ligands of NK cell 
activating receptors. Thus, 
despite expression of MHC 
class I molecules, the activating 
signals override the inhibition 
mediated by inhibitory KIRs. 
Reprinted with permission. 
Published in [2]. 
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essential issues to control for in the transplantation. In order to reduce the risk and 
severity of potential GvHD, the cells for transplantation are obtained from donor with 
maximal HLA-match. The first choice of donor is a sibling and the next possibility is 
to find a HLA-matched unrelated donor [105]. NK cells from different individuals also 
express different repertoires of KIR receptors. Therefore, it is possible to find a donor 
with NK cell subsets that do not recognise some of the recipients’ HLA molecules. 
Thus, these NK cells are potentially highly cytotoxic for that individuals’ cancer cells 
(Fig. 15). Normal recipients’ cells would be spared from allogeneic NK cell-mediated 
killing due to the absence of stress ligands for the activating NK cell receptors (Fig. 
15).  
Figure 15. The KIR receptor – HLA mismatch hypothesis.  
Donor’s NK cells expressing 
KIR receptors that do not 
recognise recipient’s MHC 
class I molecules are 
activated by activating 
ligands expressed on tumour 
cells and kill the tumour cells 
due to the absence of 
inhibitory signals. Healthy 
cells are spared due to the 
lack of activating ligands. 
Reprinted with permission. 
Published in [2].
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1.4.6.3 NK cells in immune-stimulatory anti-cancer therapies. 
One of the promising anti-cancer therapeutic strategies is to stimulate potent anti-
tumour immune responses. Several experimental therapies have been demonstrated to 
augment the capacity of endogenous NK cells to kill the tumour cells. An example of 
such effect can be targeting indoleamine-2,3-dioxygenase (IDO) in cervical cancer 
[106]. This enzyme is involved in tryptophan degradation thus expression of IDO on 
tumour cells is considered as one of the immunosuppressive mechanisms via 
tryptophan deficiency affecting T cells [106]. The study of Sato et al. demonstrated 
that down-regulation of IDO induced NK cell accumulation at the tumour site and 
inhibited the tumour growth [106]. Harnessing NK cell – mediated cytotoxicity with 
use of tumour specific antibodies to induce ADCC is a commonly investigated 
strategy, as shown with trastuzumab and cetuximab (humanised anti-EGFR mAbs) for 
treatment of breast cancer [107, 108]. An interesting approach is the use of 
immunoligands. These are fusion proteins that recognize tumour – specific antigen and 
contain ligands for the NKG2D activating receptor. Several immunoligands have been 
already tested in vitro and in vivo, like for example immunoligand targeting prostate-
specific membrane antigen (PSMA) in prostate cancer [109] and CD138 on multiple 
myeloma cells [110]. A number of studies investigated NK cell – stimulating therapies 
against glioma. For example, Avril et al. reported that NK cells in combination with 
cetuximab efficiently kill GBM cells in vitro via ADCC [111]. The work of Alizadeh  
et al. demonstrated that therapy with CpG-oligodeoxynucleotides (CpG-ODN), a 
ligand for toll-like receptor 9 (TLR9), stimulated the host NK cell - mediated immune 
responses in vivo and induced resistance to tumour re-challenge [112]. NK cells 
functionality involves also interaction with other components of the immune system, 
like for example cross-talk with DCs [113]. Therefore DCs vaccinations may 
potentially stimulate both T cells and NK cells. Indeed, Pellegatta et al. observed 
increased frequency of circulating NK cells and increased NK cell-mediated IFNȖ
production in a subset of patients receiving DC vaccines [114]. Moreover, this effect 
was associated with improved patients’ survival. On the other hand, some experimental 
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therapies, like virotherapies, might be negatively influenced by endogenous NK cells, 
due to their ability to recognise virus-infected cells [115].  
1.4.6.4 Clinical trials investigating NK cell activity against GBM. 
One of the broadly investigated cellular therapies against GBM is the adoptive transfer 
of immune cells. In this approach patients own immune cell are isolated from 
peripheral blood, cultured and/or modified ex vivo and transferred back to the patient 
systemically or directly to the tumour site. To date, several clinical trials utilized 
lymphokine activated killer (LAK) cells combined with IL-2 injections [116] and one 
trial used NK cells obtained from patients’ peripheral blood lymphocytes by selective 
ex vivo expansion [117]. LAK cells are a mixture of effector cells, mainly CTLs and 
NK cells, derived from peripheral blood mononuclear cells (PBMCs) by culturing 
under specific conditions. The composition of LAK cells depends on the donor and 
culture conditions. Clinical trials using autologous LAK cells combined with IL-2 
injections published so far reported partial efficacy and moderate toxicity [116]. 
Ishikawa et al. tested pure NK cell – based therapy against recurrent malignant glioma 
and reported tumour regression measured by MRI in 4 of 9 patients [117]. These 
attempts show the potential of NK cells as effectors against GBM, however, further 
studies are required to reveal the exact mechanism of action and in the case of LAK 
cells – based therapies, the cellular population involved should be characterised in 
detail. 
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2. Methodological considerations 
2.1 Multiparametric flow cytometry 
Flow cytometry is a fluorescence – based, powerful analytic tool with multiple 
applications, such as cell cycle analysis, phenotyping and quantitative functional assays 
like proliferation and cytotoxicity assays. This technique enables also sorting of viable 
cells of certain properties from the suspension containing mixed cell populations. In 
principle, single cells pass one by one through a laser beam and the light signal 
scattered or emitted by the cell is detected, amplified and recorded on a computer.  
2.1.1 Flow cytometry – based phenotyping 
Flow cytometry can be used to detect the expression of molecules of interest on the 
cells in the studied sample. The cells are labelled with specific primary antibodies and 
then incubated with secondary antibodies conjugated to fluorochromes – molecules 
that emit light within specific wavelength range when excited by a laser. Currently, 
there are many specific fluorochrome – conjugated antibodies available on the market 
so that direct staining can be performed. Then the data are acquired by the flow 
cytometer and can be further analysed using dedicated software. The essential data 
obtained include the number of events recorded and mean fluorescence intensity 
(MFI). Depending on the capacity of the flow cytometer (number of lasers, detectors 
and optic filters available), up to 16 parameters can be detected simultaneously. The 
basic parameters are forward scatter (FSC) and side scatter (SSC). The FSC signal is 
proportional to the size of the cell and SSC signal reflects the cell’s complexity and 
granularity. 
Depending on the quality of the sample analysed and the experimental procedure, 
analysed cell suspensions may contain considerable amounts of dead cells, debris and 
doublets (two cells that clumped together) that need to be excluded from analysis. 
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Doublets can be distinguished from singlets for example on the SSC-A vs. SSC-H plot. 
Debris are usually easy to exclude based on the FSC vs. SSC plot, where they form a 
separate population of smallest signal intensity (small size and minimal complexity).  
In order to separate viable cells from dead cells, the sample has to be incubated with a 
specific dye that stains dead cells. It may be, for example, a DNA dye that does not 
cross the intact membrane of viable cells, but can enter the dead cell via a 
compromised membrane. Then events of high fluorescence intensity will represent 
dead cells, while events of minimal (the same, as unstained cells) will represent viable 
cells. There are many commercially available dyes of different properties in terms of 
excitation and emission spectrum and some of them are designed for specific 
experimental conditions, like staining fixed and permeabilized cells.   
Simultaneous analysis of many fluorescence parameters enables distinction of several 
phenotypically different cellular populations and subsets and investigating co-
expression of different molecules within a complex sample. However, it is a very 
complex task due to the spectral overlap between emission spectra of the 
fluorochromes used in the analysis. Therefore, the experiment should be carefully 
designed to reach the balance between numbers of markers needed to be analysed 
simultaneously and the predicted complexity of data analysis. If possible, 
fluorochromes with minimal spectral overlap should be chosen for use within the same 
sample. Also, samples stained with only one dye or fluorochrome-conjugated antibody 
should be recorded in order to calculate the compensation. The compensation is a 
proportion of signal assigned to specific detector that is overlapping with signal 
detected by other detector(s) and should be subtracted. A proper choice of optic filters 
may also help in obtaining optimal measurement conditions. Long pass filters (LP), 
band pass filters (BP) and short pass filters (SP) limit the detected emission signal to 
specific wavelength range.  
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2.1.2 Advantages and limitations 
The main advantage of flow cytometry is the possibility of measuring the expression of 
several molecules simultaneously. Certain cellular subsets cannot be identified within 
heterogeneous samples with use of only one or even two phenotypic markers. An 
example may be detection of Tregs in the sample containing all types of leukocytes. 
With flow cytometry it is also easy to obtain quantitative data, like the proportion of 
cells expressing a particular molecule (number of positive events) or the level of 
expression (MFI). However, the fluorescence intensity depends on the voltage settings 
that are usually set up each time the cytometer is turned on and thus might be different 
each time. Therefore, MFI data obtained from two independent measurements are 
often not comparable. Multiparametric analysis also often saves time and resources.  
Even though this method offers many benefits, several limitations should be taken into 
consideration. Analysing solid tissue with flow cytometry requires tissue disintegration 
to obtain single-cell suspensions, thus it does not provide information about the initial 
tissue structure. Thus, such investigation should be supported with histological 
methods. Analysis of single cell suspensions alone also does not provide direct 
evidence of cell-cell interactions. Other limitations are related to the specificity of 
antibodies and stability of fluorochrome conjugates.  
2.1.3 Flow cytometry – based cytotoxicity assays 
Flow cytometry can be also used to measure the % of lysis in the cytotoxicity assays. 
To distinguish target from effector cells, one population is labelled with a dye, e.g. 
carboxy-fluorescein diacetate succinimidyl ester (CFSE) before co-culture. After the 
co-culture of target cells with effector cells, another dye is applied to enable the 
distinction between dead and viable cells, for example 7-amino actinomycin D (7-
AAD). Finally, the numbers of viable and dead target cells are measured by flow 
cytometer and % of lysis is calculated. The advantage of this method over the standard 
51Cr release assay is that it is more sensitive and does not require radioactive labelling 
[118].  
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2.2 Relevant in vivo model 
The choice of an experimental animal model for immunotherapy studies represents a 
great challenge and is often a point of debate. To study brain cancer, several rodent 
models can be used: (1) syngeneic animal models, e.g. GL26 glioma in C57BL/6 mice 
and CNS-1 in Lewis rats (2) xenograft models, e.g. U251 cells in Balb/c mice and 
U251 cells in nude rats. The advantage of syngeneic models is that the tumour 
develops in the immune competent animal so that the model reflects interactions of 
tumour with the host immune system. However, xenograft models created by 
implanting human tumour cells into immunodeficient animals are better to use for pre-
clinical investigation of therapies targeting human molecules, like VEGF or EGFR. On 
the other hand, for studying immunotherapies, syngeneic models are usually used. 
Recently, xenograft models implanted with patient-derived tumours have been 
developed [119, 120]. They are considered to better reflect the initial patient’s tumour 
biology and accurately represent the impact of their genomic characteristics.  
2.2.1 Non-obese Diabetic/Severe Combined Immunodeficiency 
(NOD/SCID) mice 
NOD/SCID mouse model was created for the needs of haematological research [121]. 
NOD/SCID mice are a result of crossing C.B-17-scid mice lacking functional T cells 
and B cells with NOD/Lt strain characterised by functional NK cell deficiency, 
defective APCs and lack of circulating complement [121]. The C.B-17-scid mice 
harbour a mutation on the gene “protein kinase, DNA activated catalytic polypeptide” 
(Prkdc) encoding a catalytic subunit of DNA-dependent protein kinase [122]. Lack of 
the functional Prkdc gene results in their inability to express rearranged antigen 
receptors leading to dysfunction in adaptive immunity [122]. The NOD mice 
spontaneously develop autoimmune (type 1) diabetes due to the defect in insulin 
dependent diabetes (Idd) gene loci [123]. These gene loci are associated with various 
immune functions and their dysfunction result in impaired innate immune system. For 
example, the Idd1 locus is related to MHC class I and II genes, the genes on Idd3 locus 
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are considered to encode cytokines IL-2 and IL-21 and aberration in the Ctla-4 gene on 
Idd5.1 locus results in defects in immune regulation mediated by CTLA-4 receptor 
expressed on Th cells [123]. The NOD/SCID mice display following immune features: 
(1) T cell and B cell deficiency, (2) absence of C5 complement, (3) decreased NK cell 
activity, (4) defective IL-1 secretion by macrophages and (5) impaired expression of 
cytokine receptors and protein kinase C on macrophages [121]. Above mentioned 
immune defects enable efficient engraftment of xenotransplants, also human cells 
[121]. This model and its humanized version have been used to study the human 
hematopoietic stem and progenitor cells engraftment and mobilization [124] and HIV 
infection [125]. Moreover, these mice and NOD/SCID mice transfected with green or 
red fluorescent proteins (GFP or RFP, respectively) have been also used to study GBM 
[126, 127]. 
2.2.2 The rationale of using NOD/SCID mice in studying tumour – 
NK cells interaction 
The purpose of our study was to investigate the role of KIR – HLA interactions in 
allogeneic NK cell – mediated cytotoxicity against GBM solid tumour in vivo. As we 
were interested especially in investigating the impact of KIR2DS2 and KIR2DS4 
receptors, we decided to use human NK cells against human GBM. Therefore, we 
conducted the in vivo experiments in immune deficient NOD/SCID mice xenografted 
with patient-derived and in vivo passaged P3 GBM, a model established in our 
laboratory. Moreover, the endogenous NK cells in the NOD/SCID mice are not 
functional, thus they should have no impact on the experiments. Another advantage of 
using this model is that xenograft models transplanted with patients’ tumour are 
considered to resemble the biological and genetic features of the initial tumour more 
than syngeneic models. However, the critical point of using immune deficient animals 
is the absence of the host immune system interactions with the tumour. Even though 
the GBM patients are severely immune compromised due to the glioma – derived 
factors and treatment they receive, several immune aspects have been proven to play an 
important role in tumour progression, anti-tumour immunity and outcome of 
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experimental therapies, like for example the presence of Tregs. These aspects cannot be 
addressed in the immune deficient animals.  
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3. Hypotheses and Aims of the thesis 
Paper I:  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate 
with prolonged survival in glioblastoma patients despite integrated 
immunosuppressive mechanisms in the tumor microenvironment and at the 
systemic level 
Hypothesis: GBM patients may be more immunosuppressed at the systemic level 
compared to healthy, age and gender matched controls 
The aims of the study were to: 
I. Characterise the immune status of GBM patients both within the tumour 
microenvironment and in the peripheral blood compared with age and gender matched 
healthy controls. 
II. Identify the integrated mechanisms of tumour immunological escape and tolerance 
to destruction by the immune system. 
III. Identify potential therapeutic targets   
61
Paper II: Natural Killer cells in intracranial neoplasms: presence and therapeutic 
efficacy against brain tumours
The aims of this study were to: 
I. Critically review and discuss the literature investigating NK cell infiltration into 
brain tumours. The motivation was to summarise what is currently known about the 
numbers of NK cells infiltrating brain tumours, their phenotype, function and reported 
clinical trials investigating the efficacy of NK cells against brain tumours. The findings 
emphasised the need for further research on this topic, with greater use of state-of-the-
art methodologies.  
Paper III: Activated NK cells are potent effectors against glioblastoma cells due to 
activating KIR-HLA ligand interactions in vitro
Hypothesis:  
I. KIR – HLA ligand mismatch might determine the NK cell cytotoxic potency 
against GBM cells in vitro
II. Purified NK cells may be more cytotoxic effectors against GBM cells compared 
to lymphokine activated killer  (LAK) cells 
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The aims of this study were to: 
I. Identify the particular KIR-HLA ligand interactions that determine NK cell potency 
against GBM cells 
II. Compare and determine the cytotoxic potency of allogeneic pure NK cells versus 
LAK cells obtained from the same donors against patient-derived GBM cells in vitro. 
Paper IV: Purified and activated allogeneic NK cells efficiently kill human 
glioblastoma in vivo
Hypothesis:  
I. Activating KIR2DS2 and KIR2DS4 – HLA ligand interactions might determine 
greater cytotoxic efficiency of NK cells against GBM in vivo compared inhibitory 
KIR-HLA ligand mismatch  
II. Intratumoural adoptive NK cell transfer is tolerable 
The aims of this study were to: 
I. Investigate the cytotoxic potency of NK cells bearing KIR2DS2 and KIR2DS4 
receptors in vivo measuring as endpoints tumour growth and survival. The overall goal 
was to unravel the biological mechanisms of human purified NK cell – mediated 
cytotoxicity against patient – derived GBM in vivo.  
II: Identify the host cellular subtypes mediating the therapeutic efficacy 
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III: Investigate the therapeutic efficacy of one versus two doses of intracranially 
injected NK cells  
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4. Summary of results 
Paper I 
The immunohistological analysis of 65 human GBM specimens revealed that the 
immune infiltration of CD3+, CD8+ and CD4+ immune cells varied between the 
patients. The increased numbers of CD3+ cells correlated with longer survival of the 
GBM patients independently of the other established prognostic factors. We observed 
decreased Th cell proportion, increased expression of CTLA-4 (CD152) inhibitory 
receptor on Th cells and increased plasma concentration of IL-10 in GBM patients’ 
peripheral blood compared to healthy controls. There was no difference in proportions 
of CD4+CD25highFoxp3+ Tregs between the patients’ and controls’ peripheral blood. 
Tumour infiltrating CTLs and Th cells downregulated the expression of CD28 
stimulatory receptor and L-selectin CD62L. Moreover, tumour infiltrating CTLs 
displayed decreased expression of CD56. Within the patients’ GBM biopsies we 
detected the presence of CD8+CD28-Foxp3+ Tregs, previously not described in gliomas, 
while CD4+CD25highFoxp3+ Tregs were absent. We also detected small populations of 
NK cells and B cells. We observed substantial proportions of macrophages/microglia 
within the tumour microenvironment that expressed inhibitory receptors 
immunoglobulin like transcript 2, 3 and 4 (ILT2, ILT3 and ILT4) as well as HLA-G 
and HLA-E, while small proportions expressed co-stimulatory molecules CD40, CD80 
and CD86. Almost all of the tumour cells expressed classical MHC class I molecules 
HLA-A,B,C, while only minimal proportions expressed non-classical HLA-E and 
HLA-G. MICA and Fas were expressed on 24.53% and 21.54% of tumour cells, 
respectively. All tumour cells were FasL negative. Interestingly, a proportion of 
tumour cells expressed an ectonucleotidase CD73, while the expression of CD39 
ectonucleotidase was restricted to immune cells. Taken together, these findings 
suggest, that despite multiple escape mechanisms, at least a proportion of tumour cells 
might be susceptible to immune cell – mediated clearance as indicated by positive 
correlation of increased immune cells infiltration with prolonged patients’ survival. 
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However, some immune cell subsets might mediate tumour – driven 
immunosuppression, thus supporting the tumour development.  
Paper II 
There is currently limited knowledge available regarding the role of NK cells in the 
immune surveillance of brain tumours. Given the potentially important role that NK 
cells may exert in controlling brain tumours and the fact that various therapies used for 
brain tumor patients may influence the efficacy of these cells, a critical review of the 
literature was undertaken. The literature investigating the degree of NK cell infiltration 
and functionality in the brain tumours revealed a great variation in the conception of 
the role of NK cells, and a remarkable paucity of research within this topic. Moreover, 
most of the studies were conducted before the development of novel methods enabling 
specific detection or isolation of NK cells. On the other hand, increasing numbers of 
publications demonstrate the anti-glioma potential of NK cells in vitro and in vivo. 
This is demonstrated directly using NK cells as therapeutic effectors or indirectly by 
characterising their mechanisms of modulating the therapeutic efficacy of various 
experimental treatments.  
Paper III 
The freshly isolated (resting) NK cells were predominantly CD56dimCD16+ in contrast 
to ex vivo cultured (activated) NK cells that were mostly CD56brightCD16+. There was 
no difference in expression of NK cell receptors: NKp46, NKG2A, NKG2D, 
KIR2DL1, KIR2DL2/3, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2/1 between the 
resting and activated NK cells. The major cell population within the LAK cell were T 
cells (72 ±12%) followed by NK cells (18 ±6%). Patient-derived GBM cells were 
phenotyped using flow cytometry. Almost all P3 and 2010-20-I cells (82.4% and 
98,9%, respectively) and half of 2012-018 cells (50,3%) expressed HLA-ABC. The 
expression of the non-classical HLA-E and HLA-G, and of the tumour stress ligands 
MICA, MICB and ULBPs was none or minimal. On the genomic level, 2012-018 cells 
possessed genes of known HLA-ligands for all KIRs, while P3 and 2010-20-I cells 
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missed the genes of HLA-ligands for KIR3DL2. NK cell donors displayed different 
KIR genes repertoire. Allogeneic activated NK cells killed patient – derived GBM 
cells (n=3) more efficiently than resting NK cells and LAK cells obtained from the 
same donors (n=8) in vitro. The NK cell potency was donor- and dose – dependent. 
The inhibitory KIR gene repertoire did not directly correlate with NK cell cytotoxic 
efficiency against the same GBM cells. In the majority of cases, the most efficient NK 
cells possessed activating receptors KIR2DS2 and/or KIR2DS4 genes. However, the 
expression of KIR2DS2 and KIR2DS4 receptors on NK cells was low or moderate. 
Blocking the KIR2DS2 and/or KIR2DS4 receptors with blocking antibodies minimally 
abrogated the NK cell-mediated lysis in 2 out of 4 donors against P3 and 2012-018 
GBM cells. Blocking those receptors in combination with blocking NKG2D receptor 
resulted in additive cytotoxic effects. Taken together, these results suggest that 
KIR2DS2 and KIR2DS4 activating NK cell receptors may contribute to increased anti-
tumour effect mediated by allogeneic NK cells in vitro, partially independently of 
inhibitory KIR – HLA ligand mismatch. 
Paper IV 
Due to the findings of the potential role of KIR2DS2 and KIR2DS4 in determining 
cytotoxic potency of NK cells against GBM reported in paper III, we embarked on 
investigating the hypothesis that KIR2DS2 and KIR2DS4 activating receptors 
determined greater cytotoxic potency compared to inhibitory KIR-HLA ligand 
mismatch of purified NK cells against solid GBM in vivo. In vivo study resembles 
patients’ condition more accurately than in vitro experiments and enables the 
evaluation of the impact of NK cell efficiency on tumour growth parameters and 
animal survival, as well as by assessment of the possible toxic effects. Purified, ex vivo
expanded NK cells obtained from 2 healthy donors with different KIR gene repertoires 
were used for intracranial injection into P3 GBM bearing mice and for in vitro
cytotoxicity assays against P3 GBM cells maintained in culture for 2 and 3 weeks. The 
two donors displayed different cytotoxic potential against patient – derived GBM cells 
in vitro. Donor A lacked genes encoding KIR2DL2, KIR3DL1 inhibitory receptors 
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indicating greater inhibitory KIR-HLA ligand mismatch. This situation reduced the 
inhibitory signals to NK cells allowing penetrance of activating signals, however, this 
donor lacked the KIR2DS2, KIR2DS4 activating receptors. In contrast, donor B 
possessed activating KIR2DS2 and KIR2DS4 and all inhibitory KIR genes matched to 
their cognate HLA ligands indicating the presence of strong inhibitory signals. In 
addition, this donor lacked activating KIR2DS1 and KIR2DS5 genes.  These two 
donors allowed us to investigate the contribution of (1) inhibitory KIR-HLA ligand 
mismatch in the absence of KIR2DS2 and KIR2DS4 and (2) the contribution of 
KIR2DS2 and KIR2DS4 activating receptor-ligand interactions in the absence of 
inhibitory KIR-HLA ligand mismatch. After 2 weeks culture, donor B’s NK cells were 
more cytotoxic than donor A’s NK cells against the same GBM target cells in vitro.  
However, intracranial injection of a single dose of 106 NK cells from each donor 
improved the survival of human GBM – bearing NOD-SCID mice compared to the 
control group. However, treatment with NK cells from donor B resulted in better 
outcome of animals as demonstrated by prolonged animal survival, reduced 
proliferation, increased apoptosis of the tumour cells and reduced angiogenesis within 
the tumour tissue. On the other hand, treatment with double dose of 106 NK cells did 
not improve animal survival compared to controls. Using flow cytometry phenotyping 
we demonstrated increased recruitment of macrophages into the brain of all treated 
animals compared to controls. However, a higher proportion of tumour-infiltrating 
macrophages of single dose treated mice expressed F4/80, IL-7 receptor (CD127), 
while increased proportions of microglia expressed CD40 compared to the 
macrophages and microglia in double dose treated mice and controls. We also 
observed up-regulated expression of nestin and HLA-ABC on the tumour cells in 
single dose treated animals compared to double dose treated and control groups. Taken 
together, these results may confirm the role of KIR2DS2 and/or KIR2DS4 in NK cell – 
mediated cytotoxicity against GBM in vivo. Moreover, these findings suggest that 
treatment with NK cells results in recruitment and stimulation of endogenous immune 




Immunotherapy is considered to be a promising novel treatment for GBM patients 
[128]. Several strategies of cellular therapy have already been tested including 
adoptive T cell [129], LAK cell [116] or NK cell transfer [117] and dendritic cell 
vaccination [114, 130]. However, it is of great importance to resolve the patients’ 
immune status and potential mechanisms of tumour-induced immunosuppression and 
immune escape, as it may influence the success of the experimental immune-based 
treatment. A number of studies investigated glioma-induced immunosuppression, as 
reviewed in Dix et al. and Gomez et al. [63, 66] Our research (paper I) confirmed the 
prognostic significance of immune infiltration in GBM reported by other groups [49, 
50, 53, 54]. We found that increased CD3 positive T cell infiltration was associated 
with improved outcomes independent of age at diagnosis and anti-tumour treatment. 
Moreover, increased CD8 positive cell infiltration had a modest association with 
patient survival. The observation that MGMT promoter methylation was not 
significantly correlated with patient survival might be explained by the relatively small 
sample size and that we analyzed samples from only one clinical center. Future work 
will be required to validate these findings with larger patient cohorts obtained from 
multicenter clinics. Moreover, we outlined novel interconnected mechanisms of 
GBM’s evasion from the immune system and indicated possible therapeutic targets. 
Systemically, we reported increased expression of the inhibitory receptor CLTA-4 on 
Th cells. The diminution of CTLA-4 expression seems to be a predictive survival factor 
following DC vaccination [131]. This upregulated CTLA-4 might be a potent 
therapeutic target with ipilimumab as demonstrated for patients with melanoma [132, 
133]. However, in contrast to other reports [134, 135], we found no significant 
difference in the proportions of CD4+CD25highFoxp3+ T regulatory cells between the 
patients’ and donors’ peripheral blood. As Fecci et al. demonstrated that the increased 
Treg fraction was patient dependent, and as we tested a small sample size it could 
explain why we did not obtain similar results [135]. 
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We detected the presence of CD8+CD28-Foxp3+ Tregs in 60% of the tested GBM 
biopsies. This is a novel finding and may explain the modest correlation of CD8+
infiltrates with patients’ survival. This Treg subpopulation is considered to be induced 
by cancer at the tumour site and it induces IL-10 - mediated immunotolerization of 
antigen presenting cells by down-regulating the expression of co-stimulatory molecules 
CD40, CD80 and CD86, and up-regulating the expression of inhibitory receptors 
ILT2,3,4 [136, 137]. Thus we phenotyped the tumour infiltrating 
macrophages/microglia and we could demonstrate the presence of all above mentioned 
features of CD8+CD28-Foxp3+ Tregs – induced immunotolerization. Analysis of the 
plasma further demonstrated elevated levels of IL-10 in the patients’ plasma compared 
to controls. We observed a substantial expression of CD39 and CD73 
ectonucleotidases within the tumour microenvironment. These enzymes catalyse the 
degradation of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to 
adenosine that at elevated extracellular level suppresses T cells [138, 139]. 
Interestingly, CD73 was expressed almost exclusively on tumour cells while CD39 
expression was restricted to tumour infiltrating immune cells, suggesting that GBM 
might dynamically adapt to its immune microenvironment. Down-regulation of the 
expression of classical MHC class I molecules in order to avoid CTLs – mediated 
cytotoxicity and expression of the non-classical MHC class I molecules, HLA-E and 
HLA-G, to escape NK cell – mediated lysis are frequently observed immune escape 
mechanisms in cancer [140-142]. However, inverse results were obtained in our study. 
Almost all the tumour cells within GBM biopsies expressed HLA-ABC that probably 
protects them from endogenous NK cells, while they were negative for HLA-E and 
HLA-G. On the other hand, a proportion of tumour cells might be susceptible to anti-
tumour immune responses due to the expression of Fas receptor that, upon binding its 
ligand expressed on NK cells and CTLs induces cell apoptosis. The tumour cells also 
expressed MICA that is a ligand for the NKG2D activating receptor that is expressed 
on NK cells and CTLs. However, the limitation of this study is the small number of 
patients, especially those available for flow cytometry – based phenotyping. Moreover, 
70
the conclusions made based on the cells’ phenotype would need to be supported by 
functional data to be more robust. 
The beneficial effect of immune cell infiltration into the tumour site and potential 
susceptibility of some GBM cells to immune – mediated destruction provides a 
rationale for developing immunotherapy for GBM. One of the promising strategies is 
the adoptive transfer of cytotoxic lymphocytes: CTLs and/or NK cells. However, as 
reviewed in paper II, little is known about NK cell infiltration into the brain tumours, 
their functionality and prognostic significance. In spite of that, emerging functional 
studies in vitro and in vivo demonstrate the anti-tumour potential of NK cells against 
GBM. Moreover, a number of clinical trials tested the treatment of GBM patients with 
autologous LAK cells [116] that are composed of a mixture of effector cells (mostly 
CTLs, Th cells and NK cells) derived from patients’ peripheral blood lymphocytes. 
One trial used pure autologous NK cells [117]. The use of autologous LAK cells or 
NK cells demonstrated partial efficacy and moderate adverse effects (mostly oedema, 
self-limiting fever, and headache) [116, 117]. 
Based on our finding that GBM cells express classical MHC class I molecules 
recognised by inhibitory KIR receptors of endogenous NK cells, we hypothesised that 
donor derived, allogeneic NK cells might be more effective against GBM than 
autologous cells. Allogeneic NK cells have been demonstrated to mediate graft vs. 
leukemia effect (GvL) in leukemia patients receiving hematopoietic stem cell 
transplantation (HSCT) due to the receptor –ligand mismatch that occurs between KIR 
receptors expressed on donor’s NK cells and MHC class I ligands expressed on the 
recipients’ cells [98]. In our study (paper III) we investigated in vitro if the same 
mechanism might determine NK cell potency against cancer cells derived from 
patients’ GBM that is a solid tumour. First, we demonstrated that purified and ex vivo
cultured (activated) NK cells were phenotypically CD56brightCD16bright and were more 
cytotoxic than freshly isolated (resting) NK cells that were of predominantly CD56dim
CD16+ subtypes or LAK cells obtained from the same donor. Furthermore, we 
observed that NK cells obtained from donors possessing activating receptors’ 
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KIR2DS2 and KIR2DS4 genes were more efficient against GBM cells. Interestingly, 
this donor-dependency was at least, partially independent from the degree of inhibitory 
KIR – HLA mismatch. However, the ligands for several KIRs, remain unknown, thus 
it was not possible to assess to potential role of those receptors in the efficiency of NK 
cell – mediated killing of GBM cells. Also the ligands for KIR2DS2 have not been 
identified yet, therefore, the role of this receptor in our study remains speculative. The 
strong point of our study is the use of GBM patients’ derived material instead of 
established cell lines, as it resembles the original tumour’s heterogeneity and tumour 
cells’ properties. However, it would be of great advantage to obtain low-passaged 
GBM cells from more patients with different HLA class I allelic variants. Another 
limiting factor was that KIR2DS2 and KIR2DS4 receptors were expressed on less than 
half of the NK cells within each donor positive for KIR2DS2 and KIR2DS4 genes. 
This may at least partially explain lack of the robust effect when blocking antibodies 
were used in cytotoxicity assays. It would be of potential interest to develop a method 
enabling purification of KIR2DS2 and KIR2DS4 positive NK cells and then compare 
their potency with NK cells missing those receptors.  
The results obtained with in vitro experiments (paper III) were confirmed in vivo, when 
we treated human GBM – bearing mice with human NK cells obtained from two 
donors with different KIR gene repertoire (paper IV). Although the benefit in survival 
was not statistically significant when comparing animals treated with single doses of 
donor A’s and donor B’s NK cells, we observed greater biological effect within mice 
receiving donor B’s NK cells, that possessed all inhibitory KIR genes and activating 
KIR2DS2 and KIR2DS4 genes, in contrast to donor A that lacked KIR2DS2, 
KIR2DS4, KIR2DL2, KIR3DL1. Treatment with single dose of 106 NK cells of each 
donor resulted in significantly prolonged animals’ survival compared with controls, 
while double doses of 106 NK cells with one week interval appeared to be intolerable. 
The critical point of the assessment of treatment efficiency in our study might be that 
the primary end points did not include radiological response. However, the evaluation 
of clinical response with use of MRI imaging has been questioned lately, as 
approximately 20-30% of patients display pseudoprogression resulting from local 
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treatment and/or radiation-induced necrosis [143]. Another issue could be the use of 
immunodeficient animals, thus it does not fully address all the possible interactions 
between the host’s and the grafted immune cells that may have a substantial impact on 
the treatment efficacy and overall outcome. Interestingly, we observed increased 
recruitment of endogenous microglia and macrophages in all treated animals compared 
to controls, but in mice treated with single dose NK cells the greater proportion of 
microglia expressed IL-7 receptor (CD127) that has been associated with inflammation 
[144, 145]. Mice treated with single dose NK cells also had larger proportions of 
macrophages that expressed CD40 receptors that co-stimulate NK cells via interaction 
with its ligand, CD154 [146]. Moreover, phenotyping of the tumour cells showed that 
GBM cells from animals treated with single dose NK cells up-regulated the expression 
of HLA-ABC and intermediate filament nestin that could be related to on-going 
inflammation [147-149]. A recent study conducted in our group demonstrated that the 
therapeutic effect of NK cells in vivo is mediated by IFNȖ secreted by NK cells that 
induces inflammatory immune response and transformation of microglia from tumour-
supportive M2 type into anti-tumour M1 type [150]. We speculate similar mechanism 
may contribute both to beneficial effect of single dose treatment and toxic effect of 
double dose treatments, however, further studies are required to confirm this 
hypothesis.  
Activating KIR receptors often share the same ligands with their inhibitory 
homologues, however, they bind HLA molecules with lower affinity and their 
physiological function remains elusive [81]. Thus, most studies investigating the role 
of KIRs in the context of cancer were focused mainly on the inhibitory KIRs – HLA 
ligands interactions. Nevertheless, our in vitro (paper III) and in vivo (paper IV) studies 
suggest that the activating KIRs, especially KIR2DS2 and KIR2DS4, may be also 
important for the efficiency of NK cell-mediated anti-tumour effect. Moreover, in the 
perspective of the development of allogeneic NK cell-based therapy, the repertoire of 
activating KIR genes might help to identify most suitable NK cell donors. However, 
further research is needed for better understanding the role of these receptors and 
underlying mechanisms. Furthermore, more pre-clinical studies are required to 
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evaluate the effectiveness and safety of intracranial transfer of allogeneic NK cells as 
GBM treatment.  
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6. Concluding remarks 
In summary, the findings reported in paper I confirm the prognostic significance of T 
cell infiltration in GBM and suggest that a proportion of tumour cells might be 
susceptible to anti-tumour immune response due to Fas and MICA expression. These 
observations provide a rationale for further efforts to develop immunotherapy for 
GBM patients. One of the potential targets would be the inhibitory receptor CTLA-4 
overexpressed in the peripheral Th cells of GBM patients. The most potent cellular 
effectors would be CTLs and NK cells. However, we showed that the tumour 
microenvironment is highly immunosuppressive towards T cells as manifested by the 
expression of CD39 and CD73 ectonucleotidases. Moreover, we suggest that 
CD8+CD28-Foxp3+ Tregs suppress tumour infiltrating APCs that are required for T cell 
stimulation. Therefore, NK cells seemed to be better candidates for cellular therapy 
against GBM due to their high capacity of recognising and killing the tumour cells 
without prior sensitization or co-stimulation.  
The review of literature (paper II) revealed a paucity of studies investigating NK cells 
in the context of brain tumour. Especially, reports describing tumour infiltrating NK 
cells need to be revised pending use of state-of-the art methods. However, recent 
functional studies demonstrated that employing NK cells holds a promising strategy 
against GBM.  
As we demonstrated that GBM cells highly express classical MHC class I molecules 
that may protect them from NK cell mediated lysis, we hypothesised, that allogeneic 
NK cells with KIR – HLA mismatch would be more efficient than autologous NK 
cells. On the contrary, our in vitro and in vivo studies demonstrated that donor-
dependent cytotoxicity of NK cells against GBM might be mediated by activating KIR 
– HLA interactions. This effect was partially independent of the inhibitory KIR – HLA 
mismatch. Particularly, the presence of KIR2DS2 and KIR2DS4 genes seemed to 
correlate with increased cytotoxicity in vitro, prolonged survival and better outcome in 
vivo. However, the efficacy of NK cell based cellular therapy should be further 
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evaluated in vivo and the safety and tolerable dose should be carefully assessed, as 
increased dose may result in toxic effect we could observe in our in vivo study.  This 
future avenue requires carefully designed animal models however, that can 
accommodate engraftment of biologically relevant, patient derived tumours and 
adoptive transfer of human allogeneic NK cells. Nevertheless, our research 
demonstrates a great potential to be harnessed in using activated NK cells against 
GBM.  
Summarizing, this research adds novel findings within brain tumour immunology field, 
like the presence of CD8+CD28-Foxp3+ Tregs within the tumour environment. The 
results of this study provide also a rationale for developing an immunotherapy against 
GBM, especially with use of pure and activated NK cells – an approach that has been 
poorly explored so far, with only two in vitro studies [86, 111] and one clinical trial 
[117]. Moreover, the suggested role of activating KIR receptors in NK cell – mediated 
cytotoxicity against GBM provides novel insight into anti-tumour immunity, as those 
receptors might have been unappreciated so far.  
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7. Future perspectives 
The research findings described above provide the basis and a solid rationale for 
further research within the brain tumour immunology field.  
The presence of CD8+CD28-Foxp3+ Tregs in the GBM tumour microenvironment and 
their potential role in GBM-mediated immunosuppression deserves further functional 
study to answer several questions: (1) what factors mediate the differentiation of T 
cells into CD8+CD28-Foxp3+ Tregs, (2) does this population contribute to APCs 
inhibition via mechanisms described before and (3) can any point of this mechanism 
serve as a target for adjuvant therapy? The potential of targeting CTLA-4 in GBM 
patients should also be explored.  
A growing amount of data is accruing regarding the phenotype of T cells, macrophages 
and microglia associated with brain tumour and these immune cell populations are 
continuously investigated in terms of their functionality and prognostic significance. 
However, little is known about the role of NK cells in brain tumour immunity. As 
emerging studies demonstrate the potential of harnessing NK cells’ cytotoxic potential 
against brain tumours both by adoptive LAK or NK cell transfer as well as via the 
immune stimulatory treatment, it is of great importance to investigate the NK cell 
status of GBM patients: (1) to determine whether they infiltrate the brain tumour (2) to 
investigate their prognostic significance in brain tumour patients (3) to study the 
functionality of GBM patients’ peripheral NK cells.  
Our in vitro and in vivo studies investigating the role of KIR – HLA interactions in 
determining NK cell potency against GBM demonstrated the potential of NK cells as 
anti-GBM agent and added a novel insight in the fields of NK cell biology and brain 
tumour immunotherapy that should be further explored. Intense research aimed at 
resolving the detailed mechanism of NK cell – mediated anti-tumour effect in the 
context of GBM may result in the development of potent adjuvant immunotherapy for 
GBM patients. However, translating these promising results to the clinic needs careful 
77
pre-clinical evaluation of safety and efficacy in the context of competent host immune 
system and developing optimal good manufacturing practise (GMP) methods for 
obtaining clinical grade, functional NK cells in high abundance.  The latter has been 
the rate-limiting step in translating NK cell based treatments to the clinic. Confirming 
the role of activating KIR2DS2 and KIR2DS4 receptors in the efficiency of NK cell – 
mediated cytotoxicity is paramount as this may prove to be a biomarker for identifying 
the most potent NK cell donors and amenable GBM patient recipients with the 
corresponding ligands. Moreover, several other aspects need to be considered in 
developing allogeneic NK cell – based treatment: (1) route of administration: systemic 
or intratumoural (2) patients’ immunosuppressive pre-conditioning (3) haploidentical 
matching of donors and recipients. Miller et al. demonstrated that systemically injected 
allogeneic NK cells obtained from haploidentical related donor can expand in vivo in 
acute myeloid leukemia (AML) patients and this treatment was well tolerated [151]. 
However, successful treatment with allogeneic NK cells administered systemically 
required immunosuppressive pre-conditioning in order to avoid host immune system 
reaction. Thus, injection of NK cells directly into the tumour site should be considered 
as an alternative for solid tumours, especially for brain cancer patients, as despite 
disrupted BBB, the access of immune cells into the tumour is limited. Furthermore, 
additional immunosuppressive preparation to facilitate successful allogeneic NK cell 
transfer should take into consideration the fact, that GBM patients are already 
immunocompromised due to the glioma-driven immunosuppression and treatment 
received (steroids, chemotherapy and TMZ). Finally, development of allogeneic NK 
cell – based therapy for brain tumour may require trans-disciplinary collaboration of 
specialists within the fields of neuro-oncology, haematology and transplantation.  
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